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ABSTRACT 
AIP56 (Apoptosis Inducing Protein of 56 kDa) is a toxin secreted by 
Photobacterium damselae ssp piscicida (Phdp), a gram-negative pathogen that infects 
and causes high mortality in marine fish species. The toxin causes selective death of 
macrophages and neutrophils by post-apoptotic secondary necrosis, being a key virulence 
factor of Phdp. AIP56 is an AB-type toxin, with a N-terminal A domain, which displays 
metalloprotease activity by cleaving NF- B p65, connected by a disulphide bridge to a C-
terminal B domain, involved in the binding and internalization of the toxin into the host 
cells. This structural arrangement gives AIP56 a potential to be used as a biomedical, 
pharmaceutical and biotechnological tool as already happens with other AB-type toxins, 
such as diphtheria and botulin. Given the important role and involvement of NF- B in 
proliferation, cell death and immune responses and the fact that its uncontrolled behavior 
is associated with human pathologies, such as cancer and degenerative and inflammatory 
diseases, greatly potentiates the clinical interest of using AIP56 as a biomedical tool.  
The present project was aimed at producing AIP56 chimeric proteins that could be 
directed to cells other than macrophages through replacing the AIP56 receptor-binding 
domain by protein ligands, whose receptors are over-expressed in cancer cells, and thus, 
promoting specific targeting, internalization, and intoxication towards determined cancer 
cells. As a specific purpose, two chimeric proteins were engineered by replacing the 
putative receptor binding domain of AIP56 (G374 to N497) by either -Melanocyte 
Stimulating Hormone ( -MSH) or InterLeukin-3 (IL-3), receptors that are overexpressed in 
melanoma and acute myeloid leukemia (AML) cells, respectively.  
Using molecular biology methods, we were able to clone the DNA sequences 
encoding each chimeric protein into a proper expression bacterial strain. Production of 
AIP56-IL3 recombinant protein was then attempted by screening and optimizing known 
protocols. Despite this, the recombinant protein was always obtained in insoluble state 
and, therefore, efforts were directed to develop refolding protocols. A successful approach 
has been developed and a soluble refolded chimera produced. The correct folding of the 
AIP56 domain was confirmed by in vitro testing of NF- B p65 cleavage, however, it 
remains to be elucidated whether the IL3 domain has been properly folded.   
Functional assays using human AML cell lines for testing whether AIP56-IL3 is 
able to induce NF- B p65 cleavage and cell death were performed. As neither p65 
cleavage nor apoptosis have been observed, it remains to be clarified whether this has 
been due to improper folding of the IL3 domain, precluding binding and internalization of 
the chimera into the cells, deficiency on the translocation process or to a not yet identified 
reason. Nevertheless, NF- B p65 cleavage was observed when the AIP56 catalytic 
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domain was introduced into the cell cytosol of AML cells using the anth LF/PA system 
as a delivery tool, although it did not result in apoptosis of AML cells.  
Key words: AB toxin, AIP56, NF- B, cell death, leukemia, biotechnological tool 
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RESUMO 
AIP56 (proteína indutora de apoptose de 56 kDa) é uma toxina secretada por 
Photobacterium damselae ssp piscicida (Phdp), uma bactéria patogénica gram-negativa 
que infecta e causa elevada mortalidade em espécies de peixes marinhos. A toxina 
provoca a morte seletiva de macrófagos e neutrófilos por necrose secundária pós-
apoptótica, sendo um fator de virulência chave de Phdp. A AIP56 é uma toxina do tipo 
AB, com um domínio A N-terminal que possui atividade de metaloprotease e cuja 
atividade catalítica é exercida por clivagem da subunidade p65 do NF-  ligado por uma 
ponte dissulfureto ao domínio B C-terminal, que está envolvido na ligação e 
internalização da toxina nas células do hospedeiro. Este arranjo estrutural confere à 
AIP56 potencial para ser usada como ferramenta biomédica, farmacêutica e/ou 
biotecnológica, como já acontece com outras toxinas do tipo AB, tais como as toxinas da 
difteria e do botulismo. Dado o papel importante do NF- B na proliferação, morte celular, 
e resposta imune, assim como o facto de o seu descontrolo estar associado a patologias 
humanas, como o cancro e doenças inflamatórias e degenerativas, potencia 
significativamente o interesse clinico de utilização da AIP56 como uma ferramenta 
biomédica.  
O presente projeto teve como objetivo produzir proteínas quiméricas AIP56 de 
modo a direcioná-las para células, que não macrófagos, através da substituição do 
domínio de ligação ao recetor da AIP56 por ligandos proteicos, cujos recetores estão 
sobre-expressos em células cancerígenas, promovendo assim o direcionamento 
especifico, internalização e intoxicação em determinadas células cancerígenas. Para este 
fim, duas proteínas quiméricas foram construídas pela substituição do domínio putativo 
de ligação à célula da AIP56 pela -hormona estimuladora de melanócitos ( -MSH) ou 
pela interleucina-3 (IL-3), cujos recetores estão sobre-expressos em células de 
melanoma e leucemia mieloide aguda (LMA), respetivamente.  
Usando métodos de biologia molecular, clonamos as sequências de ADN 
codificantes para cada uma das proteínas quiméricas, para posterior expressão numa 
estirpe bacteriana. A produção da proteína recombinante AIP56-IL3 foi então tentada por 
screening e otimização de protocolos conhecidos. Uma vez que a proteína foi sempre 
obtida na forma insolúvel, foram utilizados protocolos de refolding na tentativa de a 
solubilizar. Uma das abordagens resultou na obtenção de proteína quimérica solúvel. A 
clivagem in vitro da subunidade p65 do NF-
AIP56, no contexto da quimera, tem a conformação correta. No entanto, o mesmo não foi 
confirmado para o domínio IL3. 
x FCUP/ICBAS 
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Ensaios funcionais usando linhas celulares humanas de LMA para testar a 
capacidade da AIP56-IL3 clivar a subunidade p65 do NF- B e induzir apoptose foram 
realizados. Não foi observada clivagem do p65 nem apoptose, permanecendo por 
clarificar se este facto se deveu à incorreta conformação do domínio IL-3, impedindo 
deste modo a ligação e internalização da quimera nas células, se foi devido a deficiência 
na translocação da toxina do compartimento endossomal para o citosol ou se devido a 
razão não identificada. Contudo, e alternativamente, foi observada clivagem da 
subunidade p65 do NF- B quando se fez chegar ao citosol da células LMA o domínio 
catalítico da AIP56 usando o sistema antraz FL/AP (fator letal/antígeno protetor), embora 
não tenha resultado em apopotose das células.  
Palavras chave: Toxina AB, AIP56, NF- B, morte celular, leucemia, ferramenta 
biotecnológica 
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1. Bacterial toxins  
In order to successfully colonize their host, many bacterial pathogens owe their 
virulence to the production of specific proteins called toxins [25].  
Since diphtheria toxin was isolated by Roux and Yersin in 1888 [26], microbial toxins have 
been recognized as the primary virulence factor(s) for a variety of pathogenic bacteria 
[27]. In microbiology, they have been defined as soluble substances, result of the 
microbial metabolism, that are lethal to host cells or affect their function negatively even at 
very low concentrations [27]. Generally, their production is specific to a particular bacterial 
species (e.g. only Clostridium tetani produces tetanus toxin; only Corynebacterium 
diphtheria produces the diphtheria toxin) [28] and they are the major determinant of the 
virulence of the strains because, usually, virulent strains of the bacterium produce the 
toxin while nonvirulent strains do not [28]. 
As virulence factors, they play a major role in the pathogenesis of infectious 
diseases in the host. These proteins are some of the most powerful human poisons 
known and retain high activity in the outcome of the infection, contributing to the main 
lesions and clinical symptoms of the corresponding diseases [27]. Therefore, 
understanding the mechanism of cell intoxication leads both to the knowledge of the 
molecular pathogenesis and to the discovery of new aspects of cell physiology [29]. This 
basic knowledge has resulted in many applications: i) toxins are powerful tools for gaining 
insights into fundamental processes of cell biology; ii) several toxins are now used to 
combat several diseases such as cancer, inflammatory or auto-immune diseases [29, 30]. 
The different types of toxins produced by a bacterial cell can be broadly classified 
as endotoxins or exotoxins [30]. Endotoxins are part of Gram-negative bacteria, associate 
with outer membrane or the cell wall, as the lipopolysaccharide (LPS), and are generally 
available for action only after the death and lysis of the bacteria to which they belong [28]. 
Most of the protein toxins are thought as exotoxins, which are mostly proteins that are 
secreted by both Gram-positive and Gram-negative bacteria into the surrounding medium 
[30] and act on the host cells even when distanced from the site of infection.  
1.1. Bacterial exotoxins  
The bacterial exotoxins can be categorized according to different parameters, 
related with their function or main effects (e.g., enterotoxic, neurotoxic, hemolytic, 
cytotoxic, necrotic, lethal, etc). However, they are frequently pleiotropic and can influence 
different types of cells and tissues [30]. Since they show remarkable similarities in their 
mechanism of action, they are often characterized based upon on it [30]. Thus, knowing 
that some act at the cell surface and others at cytoplasmic targets, and according to their 
mode action, exotoxins can be classified into four groups [31] ( figure 1):  
4 FCUP/ICBAS 
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Figure 1. Schematic representation of the classes of bacterial protein toxins.There are four major classes of bacterial 
toxins, including: i) toxins that possess receptor-modulating activities, i.e., act by binding receptors on surface of host cell 
plasma membrane and trigger intracellular pathways; ii) toxins that bind to the host cell plasma membrane and disrupt the 
lipid membrane by pore formation or expression of phospholipase activity; iii) toxins that are injected directly from the 
bacterium into the cell by an injection apparatus that is a component of the bacterial pathogens (e.g., type III secretion 
system); iv) toxins that are internalized by receptor-mediated endocytosis, named AB toxins, where the A domain possesses 
enzymatic activity and the B domain is responsible for binding and translocation of the A domain into the cell cytosol . The 
toxin can be transferred directly from the endosomal compartment to the cytoplasm, driven by a pH-dependent conformation 
change, or can follow retrograde transport to the endoplasmic reticulum, from where they translocate to the cytosol. The 
group i) ii) and iv) often act at a site within the host that is distant from the bacterial pathogen, while the group iii) acts by 
contact with the host cell. (Adapted from [32]) 
i) Toxins that act at the cell surface by receptor-modulating activities 
This class of toxins intoxicates by acting as host receptor agonists or antagonists, 
corrupting signal transduction pathways [31]. The activation or modification of secondary 
messengers, can cause dramatic alterations to signal transduction pathways critical in 
maintaining a variety of cellular functions [27]. They exert their action without directly 
killing the intoxicated cell. Examples of these related bacterial protein toxins are: i) heat-
stable toxin a (STa), produced by a variety of enteric pathogenic organisms, which bind its 
cellular receptor, guanylate cyclase C (GC-C) receptor,  by mimicking guanylin, a protein 
ligand of GC-C, resulting in the stimulation of membrane-bound guanylate cyclase that, in 
turn, leads to an increase in intracellular cyclic guanosine monophosphate (cGMP), 
affecting electrolyte flux in the bowel [27, 33]; or ii) superantigens, mostly produced by 
Staphylocccus and Streptococcus, which sequentially crosslink the major 
histocompatibility complex II (MHC-II) to T-cell receptors, expressed at the surface of 
antigen-presenting cells and T-cells, respectively. This leads to nonspecific activation of T-
FCUP/ICBAS 
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cells, resulting in uncontrolled production of large and sudden amounts of cytokines 
causing fever, shock and death [31, 34-36]. 
 
ii) Toxins that act at the cell surface by damaging the plasma membrane  
The action of toxins that mediate cellular damage lead to the disintegration of the 
cell membrane, which may result not only in the direct lysis of cells but it can also facilitate 
bacterial spread through tissues [27]. Toxins included in this group do so by different 
mechanisms: enzymatic degradation of the lipid membrane (e.g., hyaluronidases, 
collagenases and phospolipases) [27] or pore formation. In this last one, as its name 
suggests, bacteria release pore-forming toxins (PFT), which form stable multimeric 
structures of different size and molecular selectivity [31] that insert into the membrane 
(insertion as an -helix to - PFT) [33], causing membrane 
permeability and ion imbalance [30, 33].  
 
iii) Toxins that have an intracellular target and are directly delivered by 
bacteria into the cell cytosol 
In this case, it is demanded cell to cell contact. After bacterial docking to the cell 
membrane, toxins are delivered into the cell cytosol by injectisomes, such as the type III 
secretion system, which consists in 
secretion of effectors through the inner and outer bacterial membranes directly coupled to 
the translocation across the eukaryotic cell membrane [37]. It represents a more complex 
injection machinery of virulence factor directly from bacteria to cell [38], often paralyzing 
the host cell´s ability to neutralize the bacterial pathogen [31].  
 
iv) Toxins that have an intracellular target and are internalized by receptor-
mediated endocytosis   
In contrast to the ones described above, delivery of this group of toxins into cells is 
independent of cell to cell contact, thereby acting locally and distantly of the site of 
infection. These toxins are frequently endowed with a major virulent function [31]. They 
are internalized by receptor-mediated endocytosis and reach their cytosolic target either 
by direct translocation from the endosomal compartment or from the endoplasmic 
reticulum after retrograde transport. The toxin focused in this work, an AB toxin, falls into 
this category, therefore a more detailed description is provided below.  
1.2. AB Toxins 
Many bacterial toxins achieve their high toxicity by delivering a catalytically active 
polypeptide fragment of the toxin to the cytosol of eukaryotic cells, attacking essential 
constituents [33]. Part of its great potency is due to high specific effects in the cytosol or in 
the nucleus, in most cases by enzymatic role, which leads to cell death or other effects on 
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cellular physiology in the host. In general, they act intracellularly as enzymes categorized 
in transferases, hydrolasases or lyases [29].  
A wide range of intracellular targets are described for this type of toxins and some 
of  their effects on cells can extend from inhibition of protein biosynthesis, increase in 
second messenger cyclic adenosine monophosphate (cAMP), disaggregation of the 
microfilament system to inhibition of neurotransmitter release [30] ( table 1).   
Table 1. Mode action of some AB toxins, their activity and cellular target. (Adapted from [39]) 
 
The action in the cytoplasmatic targets, by these proteins, implies that they cross a 
biological membrane to reach the intracellular milieu. However, and excluding rare 
exceptions, such as Bordetella pertussis AC (adenylate cyclase) toxin [38], many of these 
toxins are not able to directly cross the plasma membrane. Its overall structural and 
functional architecture allow them to solve this, being these organized in a so-called AB-
type structure [40]. 
Their cell entrance is via receptor-mediated endocytosis and the delivery of their 
enzymatic domain into the cytosol occurs either through the endocytic vesicle membrane 
or the endoplasmic reticulum membrane [25]. Their process of cell intoxication has been 
eptor, internalization, 
translocation of the membrane and intracellular effect [39].  
[5] 
[15]
[12] 
[11] 
[7] 
[10]
[13] 
[4]
[14] 
[20] 
[21] 
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Thus,  the intoxication process by toxins with intracellular targets, despite having 
different effects on the individual cell and on the organism as a whole, is characterized by 
a corresponding toxin structural organization in general [29]. 
1.2.1. AB toxin structure  
AB toxins are characterized by a bifunctional AB structure, being physically 
organized into distinct domains. These possess a catalytic moiety (or A domain), usually 
with enzymatic activity responsible for inducing toxicity by modifying a cellular target upon 
entry into the cytosol, and a binding moiety (or B domain) that comprises the receptor-
binding function, often providing tropism to specific cell types [33] and allowing the 
delivery of the catalytic domain into cells. In addition, the B promoter can also include a 
domain involved in membrane translocation (T) [29] that plays a role in the delivery of the 
A domain across a lipid bilayer [33].  
Though distinct functions are performed by A and B subunits in the same infection 
process, the functional domains are localized either on distinct structures of a unique 
protein chain (single-chain toxin) or on several protein chains (multicomponent toxin) [38], 
the latter being produced separately by the bacterium (figure 2). 
Single-chain toxins, related to diphtheria toxin (DT), Clostridial neurotoxins 
(tetanus neurotoxin, TeNT; and botulinum neurotoxin, BoNT) or Pseudomonas exotoxin A 
(PE), comprise the A and B domains contiguous (AB), in most cases, linked together via 
an exposed peptide loop and by an interchain disulfide bond [33].   
In multicomponent toxins different scenarios are described. In addition to an A 
subunit single polypeptide, composed of two domains (A1 and A2) linked together via a 
disulfide bond, the toxin has a B domain that possesses a pentameric form (AB5), and the 
assembly of both subunits occurs in the periplasmic compartment of the bacteria, during 
initial folding of the toxin [29]. A1 comprises the catalytic domain and A2, by penetrating 
into the central pore of the pentameric B subunit, allows non-covalently anchoring of A 
and B subunits [40]. This structure is shown for example in the cholera toxin (CT) or Shiga 
toxin (ST). Alternatively, multicomponent toxins may have multiple A subunits bound to 
the heptameric or octameric B domain (AB7/8), such as in anthrax and Clostridium 
botulinum C2 toxin [33] that, in general, self-assemble during the process of intoxication, 
at the surface of the target cell [29]. The non-covalent interaction allows the association of 
theses multiple components and the formation of the final complex toxin [25]. 
Multicomponent toxins are also reported to have AB2 and A2B5 structures, even though 
they only represent a minority of the toxins known so far. 
The structure of the cytolethal distending toxin (CDT) was shown to be an AB2 
toxin [41-44]. The CDT holotoxin consists of three subunits: CdtA, CdtB and CdtC, 
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encoded by three genes organized in one operon [45]. The CdtA and CdtC subunits are 
required to mediate the binding on the surface of the target cells, allowing internalization 
of the active CdtB, which is functionally homologous to the mammalian deoxyribonuclease 
I [43].  
Recently, the structure of the CDT-like typhoid toxin has been solved and shown to 
be an A2B5 toxin [46]. In typhoid toxin, similarly to CDT, the toxin is encoded by different 
genes organized in one operon. The CdtB gene is not associated with CdtA and CdtC, but 
to PltA and PltB, encoding, respectively, the pertussis-like toxin A (homologous to the 
pertussis toxin ADP-ribosyltransferase subunit) and the pertussis-like toxin B (homologous 
to one of the pertussis B subunits) [43]. The 2A domain comprises one unit of CdtB and 
one unit of PltA and the B5 domain comprises five PltB subunits. CdtB and PltA are joined 
by a disulphide bond that is formed by two unique cysteine residues that are absent in 
other cytolethal distending toxins [47].  
 
Figure 2. Structural organization of AB toxins subfamily. AB toxins are composed by a catalytic domain, the A moiety 
(orange and/or  green), and a binding domain, the B moiety (gray and/or  purple). They are produced by bacteria as a 
single-polypeptide precursor or as a multicomponent toxin. In the multicomponent toxin form different ways are shown: the 
toxin is composed by a single A subunit, subdivided in two (A1 and A2), linked via a disulfide bond, and a B domain 
pentameric form (AB5), occurring the assembly of both subunits in the perisplasmic compartment of the bacteria; or by 
multiple linked A subunits and a heptameric or octameric formed B (AB7/8), occurring the self-assemble of the toxin, outside 
the host cell. The proteolytic cleavage (indicated by closed arrows) is required to assemble the toxin (AB7/8) or to convert a 
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precursor molecule into an active one (AB, AB5), usually between two cysteine residues. Multicomponent toxins are also 
reported to have AB2 and A2B5 structures. 
Thus, the structure featured in AB toxins is, in part, influenced by the composition 
of B components, which allow their subdivision into subfamilies (AB, AB5, AB7/8, AB2 and 
A2B5,) and contributes to a variety of ways to arrange them (figure 2). In cellular uptake, to 
reach the cytosolic target, these toxins do so via different modes of binding that 
correspond to different structural organizations [29]. 
Given that, commonly, an AB-toxin is synthesized in an inactive form, it is required 
proteolytic processing. On the one hand, this may simply lead to the conversion of the 
precursor molecule to an active one, as happens to some single chain toxins, or to the 
complex toxins previously assembled by the bacteria, e.g. CT and ST; on the other hand, 
this processing may be required to the assembly of the toxin, such as in anthrax and 
Clostridium botulinum C2, given that the cleavage of the B moiety exposes a site that then 
binds to the A moiety non-covalently [33]. 
The proteolytic cleavage of the toxin can occur by a protease from the producing 
organism (e.g. CT or Clostridial neurotoxins) or by host proteases (often furin) [33], 
normally within the linker region flanked by two cysteine residues (figure 2). The evidence 
implicating the furin protease in the activation of toxins emerged in a systematic study of 
the activation of anthrax toxin protective antigen (PA) [48]. Rapidly was understood that in 
other toxins such as ST, DT and PE, processing is also performed by this protease [39]. 
However, for this last one, and exceptionally, it is only carried out after toxin 
internalization. In case of DT, both processing at the cell surface mediated by furin or 
furin-like proteases as action of bacterial proteases are described [49, 50]. 
Once the toxin is processed, the intoxication process will proceed. This process is 
characterized for having similar mechanisms of action, including four main steps until 
reaching the intracelular milieu: i) the binding, ii) internalization iii) translocation of the 
membrane and iv) intracellular effect [30]. 
1.2.2. Endocytosis and intracellular pathways of AB toxins 
1.2.2.1. Binding and internalization of AB toxins 
The initial step of intoxication by AB toxins relies on the specific interaction of the 
used as toxin receptors, including numerous lipids or lipid derivatives (glycolipid, 
gangliosides) and transmembrane proteins or glycoproteins [51]. The nature of the 
receptor and its localization, particularly in membrane lipid structures, such as lipid rafts, 
seem to be determinant in driving the intracellular trafficking of toxins and consequently in 
the targeting of the toxin to the organelle before it translocate to the cytosol [51]. Apart 
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exception, receptor specificity is critical for the pathogenic process, as it determinates host 
susceptibility, tissue tropism, and the nature and spectrum of the resultant pathology [40].  
Once toxins bond to their respective receptors, they are embedded in endocytic 
vesicles generated by invagination of the cell membrane [51] and are internalized into the 
host cell via different pathways. Interestingly, the multiple combinations of endocytic 
processes and intracellular transportations discovered by toxins have proven to be 
valuable in understanding cell biology, in particular, endoplasmic reticulum (ER) and Golgi 
apparatus as well as endosomes [52] . 
Most toxins are endocytosed, although by different mechanisms, before 
translocation to the cytosol. Some of these multiple ways of internalization include the well 
characterized clathrin-dependent and -independent pathways as well as caveolae/raft and 
dynamin-independent pathways [51]. As one might expect from opportunistic ligands such 
as toxins, usually one can enter the cell by more than one pathway [52]. However, the 
entry via clathrin-coated pits for DT, anthrax toxin, STis the preferential route [25]. In 
contrast, the CT is endocytosed via various mechanisms involving clathrin- and caveolin-
dependent and independent mechanism [25, 53]. 
Once into endosomes, different intracellular routes can be carried. Given that most 
of the AB toxins described belong to AB, AB5 or AB7/8, we will consider only the pathways 
followed by these toxin types. 
1.1.2.2. Translocation and/or intracellular trafficking routes 
Despite the diversity of the entry requirements and routes, most AB toxins interact 
at same point with early endosomes, and very few reach later stages of the endocytic 
pathway [25]. For some, mainly AB single chain and free multi-component toxins (AB7/8), 
apart exception, this is the final destination before translocation of the catalytic domain. In 
contrast, assembled multicomponent toxins (AB5) are only in transit in early or late 
endosomes from where they are directly routed to the trans-Golgi network, prior to 
delivery of their catalytic subunit [25]. Therefore, two main intracellular trafficking routes 
are used by these toxins, named  i) short and ii) long pathways [38], respectively. In each 
pathway, the mechanism used by different toxins in the translocation of their catalytic 
domain or component is different and based on its structure (figure 3). 
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Figure 3. Schematic representation of the intracellular routes followed by different types of AB subfamilies . Two 
main intracellular trafficking routes are used by these toxins named i) short or ii) long pathways, which differ in 
their final destination prior to delivery of their catalytic subunit (early endosome and RE, respectively) and the 
translocation mechanism of the catalytic domain into the cytosol. The short pathway is followed by free 
multicomponent chains (AB7/8), e.g. Anthrax toxin and C.botulinum C2, or single -chain toxin (AB), including DT, Clostridial 
neurotoxins and large clostridial toxins, being characterized by pH gradient that induce a conformational change and 
membrane penetration of these toxins leading to its translocation. After binding to its receptor, the toxin is internalized by 
endocytosis. The endosomal acidic pH triggers a conformational change of the B subunit allowing its insertion into the 
membrane and the formation of ion-conducting channels across this membrane through which the catalytic subunit 
translocates into the cytosol. In the long pathway, used by assembled multicomponent toxins (AB5), e.g. CT and ST, the 
route to this release extends up to the ER, where the translocation, not induced by the pH gradient, occurs via ER secretion 
machinery. After binding to its receptor, localized in raft microdomains, the toxin is internalized into endocytic vesicles from 
where it enters to the trans Golgi network for subsequent transport to the endoplasmic reticulum where retrotranslocation of 
the enzymatic A sbunits occurs. 
Abbreviators: GM1:Ganglioside; Gb3: glycosphingolipid. (Adapetd from [38]) 
1.1.2.2.1. Short trafficking pathway and translocation 
Both single-chain toxin, such as DT, BoNT and TeNT, and free multi-component 
toxins, including anthrax or C. botulinum C2 toxin, use this route to reach their target. After 
binding and internalization by endocytosis into the cell, these toxins migrate into the early 
or late endosomes, from where translocation of the enzymatic domain into the cytosol 
occurs upon a pH gradient [38]. Acidification of the vesicles is a prerequisite step for 
translocation, given that it triggers a proteolytic processing and/or conformational change 
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of the toxin, allowing the delivery of its catalytic domain through the lipid membrane of  
this compartments [38]. Thus, transmembrane pH gradient provides the driving force for 
the translocation [29].  
The different mechanism used to deliver the A subunit by the single chain toxins or the B 
oligomeric toxins, across lipid membranes, lead these toxins to be treated separately.  
a) Single-chain toxin (AB): diphtheria toxin as an example.  
The best-characterized paradigm of a single-chain toxin translocation is that taken 
by DT, secreted by Corynebacterium diphtheria [38]. The bond to the receptor is done by 
its C-terminal domain (R), carried by endocytosis into the clathrin coated vesicles and 
transported to early late endosomes. The acidic endosomal pH (pH<6) [37] triggers a 
conformational change of the B subunit, facilitating the insertion of -helices TH5 TH7 
and TH8 TH9 of the translocation domain (T) into the membrane, forming a cation 
selective pore [38, 54]. In addition, it also leads to a conformational change in the A chain, 
becoming partly unfolded and hydrophobic, which allows its insertion into the endosomal 
lipid membrane and subsequently its translocation to the cytosol via the formed channel 
[29]. The interchain disulfide bridge between A and T domains is reduced during the 
translocation process, allowing the catalytic subunit to leave behind the protomer B ion 
channel and to be refolded in the neutral pH of the cytosol. It is known that chaperones, 
together with other cytosolic factors, are also required for the translocation and refolding 
of the A domain [37]. Once in the cytoplasm, the A subunit catalysis the transfer of the 
ADP-ribose of NAD to the elongation factor 2 (EF-2) leading to the inhibition of protein 
synthesis [55]. 
b) Free multi-component toxins (AB7/8): anthrax toxin as an example  
In contrast, in free multi-component toxins (AB7/8) the translocation mechanism of 
the enzymatic component is based on pore formation through the membrane of 
endosomal vesicles. At low pH, B components (binding domains) of these toxins 
oligomerize and insert into vesicle  lipid membrane [37, 51]. This leads to the formation of 
-PFTs, that allows the release of the catalytic domain A into the 
cytosol. This mechanism of translocation contrasts with the one above described, where 
the B subunit plays an active role in the insertion of the catalytic subunit and the toxin 
interacts with the lipid membranes both by the translocation and the enzymatic domains 
[51].  
Since in these toxins, the enzymatic and binding components are distinct 
constituents, each type of protein can be assembled separately, forming structures 
appropriate for an efficient translocation [39]. For toxins in this group, the anthrax toxin is 
the best characterized [51].  
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The anthrax enterotoxin, produced by Bacillus anthracis, unlike AB toxins 
described above, has a tripartite structure, consisting of three independent polypeptide 
chains: a cellular binding moiety, protective antigen (PA), and two catalytic moieties of the 
toxins, lethal factor (LF) and edema factor (EF) [56]. During infection, PA (PA83) binds to 
the cell surface receptors, capillary morphogenesis protein 2 (CMG2) or tumor 
endothelium marker 8 (TEM8) receptors, and its proteolytically processing by furin or 
furin-like proteases result in the formation of a 63 kDa C-terminal fragment (PA63) and the 
liberation of a N-terminal fragment (PA20 ) [37, 56]. The fragment PA63 then spontaneously 
forms a heptamer or octamer ring-shaped structure often referred to as the pre-pore [57]. 
It is now known that the PA can also be processed in circulation by unidentified proteases, 
resulting in PA63 [55]. In both cases, the pathway that follows is the same, as described 
below. The PA63 oligomer receptor complex is capable of binding three EF and/or four LF 
molecules and then is internalized through a receptor-mediated endocytic pathway, via 
clathrin coated pits [58]. Once in the endosomes, acidic conditions induce the conversion 
of the PA63 oligomer pre-pore in to a protein-conducting channel (pore) in the membrane, 
through which LF and EF are translocated into the cytosol to exert their cytotoxic effects: 
the metalloprotease LF cleaves MAP kinases kinases, inhibiting it, and the EF increases 
the cAMP level [55]. 
1.1.2.2.2. Long trafficking pathway and translocation 
In some toxins such as assembled multicomponent toxins (AB5), the delivery of the 
catalytic domain into the host cell happens after the retrograde transport through the Golgi 
apparatus and the ER [51]. This is designated long pathway and it is related to the CT and 
ST. In contrast to the short pathway, in which translocation of the catalytic domain occurs 
in early-late endosomes, in the long pathway, the route to this release extends up to the 
ER.[51]. In addition, the pH gradient does not appear to induce a conformational change 
and membrane penetration for these toxins [29]. 
a) Assembled multicomponent toxins (AB5): Cholera toxin as an example 
Here, the CT is taken as an example of a toxin that uses this delivery route. It is an 
oligomeric protein produced by Vibrio cholera, composed by an A subunit that, although 
being synthesized as a single polypeptide chain, is post-translationally modified through 
the action of a V. cholerae protease generating two fragments, CTA1 and CTA2, which 
however still remain linked by a disulphide bond [59]. These two fragments are bond with 
a ring-shaped pentamer formed by B-subunits. The assembly of the toxin results in a 
hexameric protein complex and occurs in the bacterial periplasm [53]. Its binding to the 
ganglioside (GM1) receptor, localized at the epithelial cell surface in raft microdomains 
[51], allows it to internalize via different pathways, such as lipid raft/caveolae mediated 
14 FCUP/ICBAS 
Biotechnological and clinical potential of AIP56 toxin 
 
endocytic pathway, clathrin mediated endocytic pathway or ADP-ribosylation factor 6 
(Arf6)-associated endocytic pathway [60] to the Golgi via early and recycling endosomes. 
In the perinuclear region of the Golgi, the toxin enters to the endoplasmic reticulum and 
the catalytic domain is released from the rest of the toxin and transferred into the cytosol, 
through the Sec61 channel, in an unfolded state. Once in the cytosol, it is folded and the 
CT enzymatic domain binds to NAD and catalyzes the ADP ribosylation of GTP-binding 
protein G of the adenylate cyclase complex, increasing intracellular cAMP [60].  
Despite these examples, other alternative intracellular pathways are reported. 
In the last decades, these discoveries have been proving that, although the toxins 
have been very helpful in detecting and clarifying the role of different molecules, such as 
G proteins [27], they are also a powerful tools to reveal new pathways in intracellular 
transport, namely, types of endocytosis, membrane transport to various intracellular 
destinations such as the Golgi apparatus and the ER as well as to late 
endosomes/lysosomes or translocation to the cytosol  from endosome, for example, by 
DT [27]. In fact, revelation that molecules can be transported from the cell surface through 
the Golgi apparatus and to the ER has been made by studies of ST [61].  
Since the discovery of a diversity of bacterial toxins, its properties and molecular 
mechanisms of toxin action are not only a relevant topic of study for those interested in 
the pathogenesis and immunology of infectious diseases but also they have been used as 
an instrument for gaining insights of fundamental processes of cell biology [62], allowing 
remarkable advances both in basic and applied sciences. Furthermore, knowledge about 
their action on cells can be used to combat infectious diseases where such toxins are 
involved and a whole new field of research takes advantage of their ability to enter the 
cytosol, given its structural characteristic and functional architecture, for therapeutic 
purposes in connection with a variety of diseases [27]. 
1.3. Toxins as pharmacological tool 
In a pharmacological context, several properties characterize toxins and make 
them unique and interesting tools to be exploited in an attempt to combat numerous 
diseases, such as cancer or inflammatory diseases. The ability of acting on target cells 
independently of the presence of the producing bacteria [27], is one of them.  
Some advantages of toxins as biotechnological tools come from their high potency, 
specificity and extraordinary efficiency [63]. They act at extremely low concentrations, in 
the range of the picogram, like in the case of botulinum neurotoxins, which grants its high 
specificity [63].This is achieved, on one hand, by the enzymatic action that most of toxins 
possess, not requiring other molecules to modify the target and, on the other hand, by the 
ability to interact with high-specific cell surface receptors in certain cells [62]. In addition, 
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in most cases, the fact that its catalytic mechanisms are irreversible and these toxins have 
preference to eukaryotic targets that play pivotal roles in cellular functions, make them 
high efficiency tools. 
Some years ago, bearing in mind the properties mentioned earlier as well as the 
discovery of the ability to replace domains in intracellular target toxins, depending of the 
purpose of their use, led to the thought of AB toxins as potential biomedical, 
pharmaceutical and biotechnological tools. 
1.3.1. AB toxins as biotechnology tool 
In the last decades, the resolution of the structural properties of AB toxins allowed 
a major breakthrough providing significant structural insights into the biological, functional 
and catalytic activity of these toxins. The discovery that these toxins are often organized 
into discreet domains that comprises a catalytic, receptor binding and translocation 
domain allowed to development them as biotechnological tools. In other words, these 
toxins (or parts of them) can be used as vectors to bring other molecules into cells, a 
toxins' ability that is of great importance in medical and pharmaceutical areas [64].  
Taking into account the main aim, all these three components can be used to 
construct a protein delivery system [27]. One of the properties exploited in these toxins is 
the possibility to transfer different molecules into cell, as enzymes, because they are able 
to cross the lipid cell membrane without major damage of cell integrity unlike lots of 
synthetic chemicals used as pharmacological tools [27]. Despite of intensive research in 
this area, the understanding of many of these mechanisms of toxin translocation, 
undeniably fascinating, remains a challenge [2].  
Other property is the possibility of changing of the receptor-binding domain, which 
often provides tropism to specific cell types. This particularity takes advantage in cases of 
cells with membrane signing, as often happens in cancer cells. In addition, as mentioned 
above, it is known that these proteins attack targets of the cell that compromise its 
functions. That being said, these properties make these toxins particularly interesting in 
treatment of diseases like cancer, whose purpose is to kill cells. The concept of 
construction bimolecular agents chemically linked or genetically fused to a toxin moiety is 
already being explored for some years [62]. 
In the late 1970s, the discovery by Yamaizumi et al. of the potency of DT for 
mammalian cells [63], the introduction of the concept of using antibodies to redirect toxin 
killing activity in a purposeful way by Thorpe et al. [64], and the strategy to link both were 
 [65].  
Immunotoxins (IT), chimeric proteins consisting of a targeting moiety linked to a 
toxin, explore the phenomenon where, as in cancer, cells overexpress several tumor 
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associated antigens, membrane receptors and carbohydrate antigens thus allowing death 
of diseased cells while leaving normal cells [65]. In immunotoxin constructs, the target 
moiety varies depending of the disease and tissue type [65]. They belong to one of two 
groups: (i) monoclonal antibody or single chain variable fragment (scFv) specific for the 
overexpressed tumor-associated antigen or membrane receptor; or (ii) natural ligand for 
the membrane receptor like cytokine, growth factor or peptide hormone [62] (figure 4). In 
this last category, Melanocyte-stimulating hormone (MSH) as alpha-MSH targeted to 
melanotropin receptors (MTR1) in melanoma [66] and IL-2 were early candidates [64] to 
link to DT. Although many other toxin-based cell delivery systems are under studies for 
this purpose, PE, anthrax toxin and DT are among the top choices for immunotoxin 
development [64].  
 
Figure 4. Schematic representation of various strategies for construction of immunotoxins. Immunotoxin (IT) is a 
chimeric protein consisting of a targeting moiety linked to a toxin. The targeting moiety belongs to one of the two groups: 
antibody to surface or others including cytokines or growth factor. (Adapted from [64]) 
Mostly, but not exclusively, immunotoxins are purpose-built to kill cancer cells as 
part of novel treatment approaches. However, other applications for immunotoxins include 
immune regulation and the treatment of viral or parasitic diseases [62]. 
Although to date only one targeted toxin, DT-IL2 (termed denileukin diftitox - trade 
name Ontak), directed to the IL2 receptor, has been approved for humans (FDA approved 
for cutaneous T cell lymphoma (CTCL) therapy) [62], other immunotoxins await the 
approval of favorable results from phase III trials [65]. Numerous studies to various 
diseases are being developed and have been successful. If we examine on-going clinical 
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trials, we see these kinds of efforts persist. In many cases, the toxin constructs that 
selectively target cells are already in phase I, II or III clinic trial  [63, 65] (table 2). This is 
exemplified by DT where the receptor binding domain was exchanged with interleukin-3 
(IL3). This is a cytokine that supports proliferation and differentiation of multipotential and 
committed myeloid and lymphoid progenitors [67]. Myeloid leukemic progenitors over-
express IL3R, which is composed by two units:  
myeloid cells lack IL3R [65]. The binding of IL3 to its receptor causes rapid receptor-
mediated endocytosis on receptor coupling [68]. These characteristics were harnessed 
and IL3 has been engineered as receptor binding component of the immunotoxin. DT-IL3 
has been utilized as a potent toxin targeting Acute Myeloid Leukemia (AML) and it already 
in phase I clinical trial [69]. Other example in phase I clinical trial is ErbB2 (Her2), a growth 
factor receptor generally overexpressed in solid tumors, that is targeted by using single 
chain fragment variable (scFV(FRP5))-PE for breast, prostate, head and neck and non-
small cell lung cancer [63].  
Table 2. Clinically evaluated/under evaluation of immunotoxins (AB toxins) used to solid tumors, hematologic 
malignancies and autoimmune disorders. (Adapted from [64]  
 
The advances and successes in immunotoxins are the result of extensive research 
and cooperation between different scientific areas. A better knowledge of the toxins 
described some years ago, such as the boundaries of each domain as well the role played 
by specific amino acids regions in their functions, have allowed an undeniable 
breakthrough in the development of immunotoxins. For example, we already are in the 
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presence of the third generation of immunotoxins, where improvements of molecules, like 
the removal of the immunogenic amino acids, are being made [65]. In fact, in spite of the 
potential shown by bacterial toxin-based chimeric proteins, the immunogenicity has been 
one of the several obstacles that has limited their clinical application [62]. However, the 
improvement of immunotoxin design, as described above, has been trying to minimize 
these side effects. 
Further, the discovery of new AB toxins with different target moieties of the ones 
we know so far, such as nuclear factor- B (NF- B), which play a crucial role in several 
diseases, have also opened doors in the search to treatment for them. However, 
characterization and understanding of its functions in anticipation to the scientific 
challenges and strategic priorities to use as biotechnology tool are required. An example 
of these new AB toxins is AIP56.  
2. AIP56 
2.1. AIP56-associated pathogenecity  
AIP56 (Apoptosis Inducing Protein of 56 kD) is a plasmid-encoded exotoxin, 
abundantly secreted by virulent strains of Photobacterium damselae ssp piscicida (Phdp), 
a gram-negative pathogen that infects and causes high mortality in several warm water 
fish species worldwide, including sea bass [70]. The toxin induces selective apoptosis of 
fish macrophages and neutrophils, resulting in extensive lysis of the phagocytes by post-
apoptotic secondary necrosis[71]. The fails in the removal of the apoptotic cells and 
apoptotic bodies, i.e. cellular condensation induced by the apoptotic process, lead the 
transition of the apoptotic process to secondary necrosis and subsequently cell lysis, 
which is pathogenetic [72, 73]. 
During infection, Phdp spreads through the bloodstream, colonizes various internal 
organs and secretes the AIP56 toxin [73]. Apoptosing cells, identified by an apoptotic 
morphotype, TUNEL positivity and presence of active caspase-3, are seen in foci and 
scattered in several organs including kidney, spleen and liver, which exhibit hemorrhagic 
septicaemia and granulomatous lesions [73]. Similar pathological signs are observed 
when AIP56 is inoculated alone into fish, showing that the toxin is the key virulence factor 
responsible for the Phdp-associated pathology [63, 64].   
2.2.  AIP56 structure and action  
AIP56 is classified as a single-chain AB-type toxin [74]. Analysis of its primary 
structure showed that AIP56 is synthesized as a 520 amino acid precursor protein, 
including an N-terminal signal peptide that is cleaved during secretion, originating a 497-
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amino acid mature toxin  [70]. An important features present in the N-terminal region is a 
zinc-binding signature HExxH, typicall of most zinc metallopeptidases [75], consisting of 
the amino acid sequence HEIVH [70], similarly to the tetanus neurotoxin [76]. An 
additional feature is the presence of only two cysteine residues (C262 and C298) [70].  
Homology analysis of AIP56 showed similarity with other proteins from different 
organisms [73] (figure 5), especially full-length uncharacterized homologues in Vibrio 
species but also Arsenophonus nasoniae. Furthermore, the N-terminal region (first 324 
amino acids) was found to be homologous to the non-LEE (locus of enterocyte 
effacement) encoded type III secreted effector C (NleC), conserved in several enteric 
pathogenic bacteria, while the C-terminal region share homology to an uncharacterized 
protein of Acrythosiphon pisum bacteriophage APSE-2 and to the C-terminal portion of a 
hypothetical protein of the monarch butterfly Danaus plexippus [73]. These facts, 
suggesting that AIP56 was a two-domain protein, were later confirmed by limited 
proteolysis [73].  
 
Figure 5. Schematic diagram of the AIP56´s primary structure and AIP56-related proteins. Grey: signal peptide, as 
experimentally determined for AIP56 [70]; Yellow: regions with high identity to NleC and AIP56 N-terminal catalytic domain; 
Green: regions with high identity with AIP56 linker polypeptide; Orange: regions with high identity to APSE-2 and AIP56 C-
terminal domain; Red: zinc-metalloprotease signature HEXXH; White: regions with low identity to AIP56 domains, NleC or 
APSE-2. Conserved zinc-metalloprotease signature HEXXH, cysteine residues and other signaled amino acids are 
represented and numbered at their relative positions. Information about AIP56-related proteins is constantly being updated. 
Examples includes Vibrio azureus (WP_021710670.1 ) and Vibrio tasmaniensis (WP_017104811.1) (From [74])  
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As a single-chain toxin, AIP56  is organized in two distinct domains (figure 6): an 
N-terminal A domain, which displays zinc-metalloprotease activity by cleaving NF- B p65 
at the Cys39(Cys38 of human p65)-Glu40 peptide bond within the p65 N-terminal Rel 
homology domain (segment crucial for DNA interaction), and a C-terminal B domain, 
involved in the binding and internalization of the toxin into the host cells [74]. These two 
domains are connected by a disulphide bridge, formed by C268 and C298, which plays a 
role in the intoxication process but, apparently, may not be an absolute requirement for 
toxicity. In addition, the integrity of the linker region between the two cysteine residues is 
needed for toxin internalization [74]. AIP56-mediated depletion of NF- B p65 likely 
explains the disseminated phagocyte apoptosis observed in Phdp infections, which 
contributes to subvert the host immune response and determines the outcome of the 
infection [70, 74, 77]. 
 
Figure 6. Schematic representation of AIP56. The 497-amino acid mature toxin (gray) has two domains: an A domain and 
a B domain linked by a disulphide bridge between cysteine 262 and 298. The conserved zinc-metalloprotease signature 
(HExxH) is represented and numbered at its relative positions. The cleavage site resulting from limited proteolysis by 
chymotrypsin is depicted. ( Adapted from [74]) 
Interestingly, both AIP56 and Nlec were found to have a similar proteolytic activity 
towards p65 within its N-terminal region, by cleavage of this subunit at the same peptide 
bond [74, 78]. Contrasting are the requirements for their activity since NleC requires a 
type III secretion machinery, while AIP56 has an intrinsic ability to reach the cytosolic 
target owing to its structure-function, namely a C-terminal B domain responsible by its 
delivery into the cell [74]. 
As an AB toxin, AIP56 enters cells through a multi-step process. Analogously to 
other AB toxins, such as DT and Clostridial neurotoxins, it is known that AIP56 is 
endocytosed by a clathrin-dependent mechanism and, triggered by the acidic endosomal 
pH, suffers conformational changes, allowing its translocation into the cytosol (in press). 
Nevertheless, the detailed molecular mechanisms leading to these observations are still 
unknown. Efforts to obtain a better knowledge about those mechanisms as well as better 
structural-function characterization of the toxin, namely, the minimal region involved in 
translocation and receptor-binding and the boundary between A and B domains, are 
presently ongoing. Yet, recent studies showed that, similarly to fish macrophages and 
neutrophils, AIP56 is also able to induce depletion of NF- B p65 and apoptosis in mouse 
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bone marrow derived macrophages (mBMDM) (in press).These results, in addition to its 
structural arrangement and how cell intoxication occurs, confers to AIP56 an enormous 
biotechnological potential and have relevant implications when considering its use as a 
therapeutic agent in situations associated with uncontrolled activation of NF- B [73], such 
as inflammatory diseases and cancer.   
The target of this toxin is an important feature, since that the transcription factor NF- B is 
also involved in several crucial cellular processes, described in greater detail below. 
3.  NF- B  
For over a quarter-century ago, Sen and Baltimore [79] firstly described the 
transcription factor NF- B (nuclear factor-kB) as a protein that bounds to a specific 
decameric DNA-sequence (5'-GGGACTTTCC-3') within the intronic enhancer of the 
immunoglobulin kappa light chain gene in mature B and plasma cells but not pre-B cells 
[80]. An intense research followed and soon afterwards it became clear that this consisted 
of a family of transcription factors, which includes a collection of proteins, conserved from 
(at least) the phylum Cnidaria to humans [81], that are expressed in almost all cell types 
and regulate many target genes with a whole variety of functions [82].   
During the past two decades, several studies have highlighted its most important 
and conserved evolutionarily role in immune, inflammatory and stress responses through 
NF- B-dependent transcription of cytokines, chemokines, cell adhesion molecules, growth 
factors, factors of the complement cascade, acute phase proteins, effector enzymes in 
response to ligation of many receptors involved in the immune recognition process, 
including T-cell receptors (TCRs) and B-cell receptors (BCRs) for example [83-85]. This 
way, it allows cells to adapt and respond to environmental changes, a process pivotal for 
survival [86]. Even though its key role, it is well-established that it acts broadly, being able 
to regulate the expression of genes outside them, influencing events that impact 
proliferation, differentiation, cell survival, apoptosis and development of a number of 
tissues including central nervous system, skin, mammary gland and bone or embryonic 
development [83]. 
So far, it is known that several external stimuli, which are continually expanding, 
can lead to its activation such as bacterial and viral infections (e.g., through recognition of 
microbial products by receptors such as the Toll-like receptors), inflammatory cytokines, 
antigen receptor engagement, upon physical (UV- or -irradiation), physiological (ischemia 
and hyperosmotic shock) to oxidative stresses [86, 87]. 
Taken into account its critical play in mediating responses to a remarkable diversity 
of external stimuli and the wide role on cell physiology it is not surprising that 
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dysregulation of NF- B is linked to multiple physiological and pathological processes such 
as inflammatory and autoimmune diseases as well as cancer [86]. 
3.1. The NF- B transcription factor family  
In mammals, the NF- B proteins family is composed of p50 (NF- B1) and p52 (NF-
B2), synthesized as pro-forms (p105 and p100, respectively) that undergo proteolytic 
process to become shorter and active DNA-binding proteins; and c-Rel, RelB and RelA 
(p65) [81]. The five members of this protein family share some structural features, 
including a conserved 300 amino acid long amino-terminal Rel homology domain (RHD), 
which is essential for dimerization, binding to cognate DNA elements and interaction with 
IkBs [82]. Structurally, the RHD is divided into three functional subdomains: the N-terminal 
domain (NTD), the dimerization domain (DiD) and the nuclear localization signal (NLS) 
[88]. In contrast, and based on their transactivation potential, the C-terminal these proteins 
are distinguishable. c-Rel, RelB, and p65 proteins contain C-terminal transactivation 
domains (TAD), necessary for transcriptional activation, often not conserved at sequence 
level across species [81]. In opposition, p50 and p52 proteins lack TAD and instead 
contain a glycine-rich region (GRR), reminiscent of the larger precursors processing p105 
and p100, respectively [89] (figure 7). As consequence, dimers of p50 and p52, which 
bind to NF- B elements of gene promoters, act as transcriptional repressors. However, 
when bound to members containing a TAD, such as p65 or RelB, they constitute a 
transcriptional activator [82]. 
 
Figure 7. Schematic representation of NF- B, I B and IKK protein family. The mammalian Rel (NF- B) proteins consist 
of five members: p65 (RelA), RelB, c-Rel and matures p52 and p50 protein, result of proteolytic processing (site of 
proteolysis are indicated by black arrows) from precursor proteins p100 and p105, respectively. All five proteins share a 
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conserved DNA-binding/dimerization domain called Rel Homology domain (RHD).The C-terminal halves of the p65, RelB 
and c-Rel proteins have transcriptional activation domains (TAD). In contrast, the C-terminal halves of the p52 and p50 
proteins possess an ankyrin repeat-containing (ANK) inhibitory domain that is removed by proteasome-mediated 
proteolysis. A glycine-rich region (GRR), remaining after this process, is present in the mature forms. The IkB family consist 
of eight members, which are typified by the presence of multiple ANK and mediate binding to the RHD of NF- B proteins, 
sequestering the complex in the cytoplasm. The IKK complex, composed by catalytic (IKK  or Ik ) and regulatory 
(IKK NEMO) subunits, phosphorylate the IkB proteins, signaling for ubiquitination and degradation.   
The domains that characterize each protein are shown. CC, coiled-coil; DD, death domain; HLH, Helix loop helix; LZ, 
leucine-zipper; NBD, NEMO binding domain; PEST, proline-, glutamic acid-, serine-, and threonine-rich region; ZF, zinc 
finger. (From  [86]) 
All members of the Rel/NF- B family can associate to form distinct homo- or 
heterodimeric complexes. These different combinations form up to fifteen different dimers, 
but it has not yet been demonstrated the physiological existence and relevance for all 
possible dimeric complexes [86]. However, the p50-p65 heterodimer clearly is the most 
abundant in most cells, being found in almost all cell types [90]. 
Collectively, NF- B transcription factor dimers bind to 9 10 base pair DNA sites, 
known as B sites, in the promoters and enhancer regions of genes, thereby modulating 
gene expression [81]. Given that different NF- B dimers have distinct DNA-binding site 
specificities for a collection of related B sites, the combinatorial diversity of the NF- B 
dimers contributes widely to the distinct transcriptional regulation [81].  
As NF- B has the ability to influence expression of numerous genes, also its 
activity is tightly regulated at multiple levels. The primary mechanism for regulating NF- B 
is through proteins termed inhibitors of NF- B (I Bs) and the kinase that phosphorylates it, 
the I B kinase (IKK) complex [86, 90].  
The I B family members possess different affinities to individual NF- B dimers and 
currently this family consists of eight members: I B , I B , I B , IkB , BCL-3 (B-cell 
lymphoma 3), I BNS, and the precursor proteins p100 and p105. They are characterized 
by the presence of five to seven ankyrin repeat motifs, which mediate their binding via 
protein protein interactions with the RHD of NF- B proteins in the cytoplasm, thereby 
making them transcriptionally inactive (figure 7). By the presence of this motifs, it is 
understood why the precursors p105 and p100 have their own internal inhibition [86, 88, 
90], therefore, away from the nucleus, preventing DNA binding and gene regulation, or in 
other words, silencing their transcriptional activity [88].   
A number of post-translational modifications also modulate the activity of the I B 
and IKK proteins as well as NF- B molecules themselves [86]. Nevertheless, other 
possible ways to regulate this pathways are already described such as the regulation of 
NF- B by upstream IKK pathways [91]. 
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3.2. Pathways of NF- B: canonical and non-canonical  
In most non-stimulated cells, NF- B complexes are sequestered in the cytoplasm 
in an inactive form via I B-bound complex. In recent years, it has become clear that there 
are at least two different pathways for NF- B activation. The two major and best-described 
pathways are known as the canonical (or classical) pathway and the non-canonical (or 
alternative) pathway (figure 8). In both pathways, the common upstream regulator is the 
activation of an I B kinase (IKK) complex, which consists of two catalytic kinase subunits 
(IKK /IKK1 and/or IKK /IKK2) and/or a regulatory subunit, a scaffold called NF- B 
essential modulator (IKK NEMO). The differential requirement for IKK subunits, stimuli 
that leads to its activation and the activation of different NF- B dimers define each one of 
these pathways.  
The canonical pathway is representative of the general scheme of how NF- B is 
regulated and activated. This is triggered by microbial products, such as 
lipopolysaccharides (LPS), flagellin or peptidoglycans [85], or proinflammatory cytokines, 
such as TNF  and IL-1, leading to activation of p65, c-Rel, RelB and p50 containing 
complexes [84]. In general terms, stimulation through receptors like cytokine receptors, 
such as Tumor Necrosis Factor-Receptor (TNFR) or IL-1 receptor (IL-1R), pattern 
recognition receptors (PRRs), such as Toll-like receptor 4 (TLR4) and antigen receptors, 
among many other stimuli, trigger signaling cascades that culminate in activation of IKK 
complex [88]. Firstly, upon recognition and binding of ligand to its cell surface receptor 
occurs the recruitment of adaptors (e.g., TRAFs, TNF receptor associated factors; and 
RIPs, Receptor interacting proteins) to the cytoplasmic domain of the receptor [81]. In 
turn, these adaptors often recruit an IKK complex that, in the canonical pathway, is 
composed of the  kinase subunits (IKK  and IKKß) and two molecules of 
the regulatory scaffold NEMO. Subsequently, the clustering of molecules at the receptor 
activates the IKK that phosphorylates the I Bs. This triggers I B polyubiquitination, 
leading to its proteasome-dependent degradation and exposure of the NF- B nuclear 
localization domain, which allows translocation of free NF- B dimers to the nucleus and 
concomitant activation of specific target gene expression (figure 8). It is known that 
depending on the accessibility of the genome, regulated by epigenetic mechanisms, and 
the cell type, thousands of different target genes can be transcriptionally activated [82].  
Alternatively, the non-canonical pathway (figure 8) is largely for activation of 
RelB/p100 complexes resulting of RelB/p52 complexes, occurring during the development 
of lymphoid organs responsible for the generation of B and T lymphocytes, dendritic cell 
activation and bone metabolism [81]. A small and certain number of receptor signals are 
known to activate this pathway, such as Lymphotoxin  (LT ), B-cell activating factor 
(BAFF), CD40 ligand (CD40L) and receptor activator for NF- B ligand (RANKL), but not 
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TNF [84, 89]. In contrast, the IKK complex involved contains two IKK subunits, but not 
NEMO. In this pathway, the ligand induced activation of NF- B-inducing kinase (NIK) 
phosphorylates and activates an IKK  complex that, in turn, leads to phosphorylation of 
p100 at its C-terminal, where are the ankyrin repeats [81], resulting in its partial 
proteolysis to p52, followed by ubiquitination, degradation and finally liberation of the 
p52/RelB complex [86].  
 
Figure 8. NF- B signal transduction pathways. The canonical (or classical) NF- B pathway is typically triggered by 
microbial products and proinflammatory cytokines, leading to activation of p65, c-Rel, RelB and p50 containing complexes. 
The binding of a ligand to a cell surface receptor (e.g., tumor necrosis factor-receptor, TNFR; Interleukin-1 receptor; or Toll-
like receptors, TLRs) leads to recruitment of adaptors molecules (e.g., TRAFSs and RIP) to the cytoplasmic domain of the 
receptor. In turn, occurs the recruitment and activation of an IKK complex comprising IKK alpha and/or IKK beta catalytic 
subunits and two molecules of NEMO, in contrast with non-canonical composed only by two subunits IKK alpha. IKK then 
phosphorylate I B leading to ubiquitination and degradation by the proteasome. The released NF- B dimers translocate to 
the nucleus to turn on target genes. In contrast, the non-canonical (or alternative) pathway is largely for activation of 
p100/RelB complexes. It is activated by specific receptor signals, such as Lymphotoxin  (LT), B-cell activating factor 
(BAFF) or CD40 ligand, which leads to the activation of NF- B inducing kinase (NIK), that phosphorylate and activates an 
IKK alpha complex. In turn, the p100 protein is phosphorylated and is lead to proteosomal processing, generating p52/RelB 
dimers. The activation of this dimers allows their translocation to the nucleus and targeting of specific B elements. 
(Adapted from [92] ) 
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Despite of the large development in the comprehension of the complex network of 
NF- B signaling pathway, some mechanisms are still to be understood. The continuing 
interest into the regulatory mechanisms that govern the activity of this transcription factor 
can be easily explained by  its association with several number of diseases in which 
dysregulation of NF- B has been implicated [86].  
3.3. Targeting NF- B in diseases 
As mentioned early, in addition to the pivotal role in the control of genes involved in 
the immune and inflammatory response, the IKK/NF- B pathway has gained recognition 
for its role as a key mediator in several diseases, namely inflammatory and metabolic 
disorders as well as in the development and progression of human cancers [84]. Although 
NF- B activity is inducible in most cells, it can also be detected as a constitutively active 
nuclear protein, in certain cell types [82]. Some examples are mature B cells, neurons, 
and vascular smooth muscle cells [82], as well as a large number of tumor cells [86], such 
as AML [93], therefore, it can exert a variety of pro-tumorigenic function [82]. For example, 
it regulates genes involved in the inhibition of apoptosis, including the tumor necrosis 
factor receptor-associated factors (TRAF1 and TRAF2), the cellular inhibitors of apoptosis 
(c-IAP1/2 and XIAP) or Bcl-XL [94]. Some of these antiapoptotic stimulus block the 
activation of caspases involved in the apoptotic pathway [95], contributing to cell survival 
and consequently progression of cancer. Regardless the diverging opinions in the last 
years, around the double and opposed role of NF- B in cellular apoptosis [96], several 
studies prompted investigators to the targeting of NF- B pathways compounds, namely 
inhibition of its activity, as therapeutic approach to control cell disorders that contribute to 
these diseases.   
The progress made in the understanding of the activation of the NF- B pathway, 
as well as in the function performed by its core elements, such as NF- B dimers, I B 
proteins and the IKK complex, allowed the development of NF- B pathway inhibitors 
aimed to control its dysregulation in several diseases. Some of these compounds include 
protein kinase inhibitors, inhibitors of NF- B-mediated reporter gene expression, also 
called transactivation inhibitors, and proteasome inhibitors [96]. Despite the success 
achieved by many of these inhibitors, some limitations, such as the non-exclusive action 
in this pathway, have contributed to the need for new agents that can modulate and be 
more effective at targeting NF- B for therapeutic use [96] . 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II  
PROJECT AIMS 

FCUP/ICBAS 
Biotechnological and clinical potential of AIP56 toxin 
29 
 
 
 
AIP56 is classified as an AB-type toxin. This protein possess a N-terminal A 
domain, which displays metalloprotease activity by cleaving NF- B p65 and, 
consequently, triggering apoptosis of phagocytes in sea bass, connected by a disulphide 
bridge to a C-terminal B domain, involved in the binding and internalization of the toxin 
into the host cells. So far, the boundaries of both the translocation and the receptor 
binding domain with the host cells remain undefined. However, bioinformatics analysis of 
of a C-terminal subdomain that may correspond to a receptor binding region. Finally, 
studies in our lab showed that AIP56 is able to cleave NF- B p65 and trigger apoptosis of 
mouse bone marrow derived macrophages in a similar way as previously described for 
fish macrophages. Therefore, in addition of what is known about not only the involvement 
of NF- B in human pathologies but also the structural arrangement of AIP56, the clinical 
interest of using AIP56 as a biomedical tool is greatly potentiated. 
With the above in mind, this work aimed at directing AIP56 chimeric toxins to cells 
other than phagocytes through the replacement of AIP56 putative receptor-binding 
domain with protein ligands, whose receptors are over-expressed in cancer cells, leading 
to the promotion of specific targeting, internalization, and catalytic activity of AIP56 
towards specific cancer cells.  
To achieve this goal, the following strategies were followed:  
i) Construction of two chimeric proteins, containing AIP56 toxin in which the 
putative receptor binding domain (G374 to N497) was replaced by either -melanocyte 
stimulating hormone (AIP56 MSH) or human InterLeukin-3 (AIP56-IL3) 
 
ii) Purification of the protein chimeras 
 
iii) Analysis of the toxicity induced by these proteins in specific cancer cells (acute 
myeloid leukemia (AML) cells and melanoma cells) 
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1. Recombinant proteins  
1.1. AIP56-IL3 and AIP56 MSH 
1.1.1. Plasmid Construction  
In this work, two chimeras were constructed: (i) AIP56-IL3, where the AIP56 
predicted binding domain (amino acid G374 to N497) was replaced by human interleukin 
3 (IL-3) and (ii) AIP56 MSH, where the AIP56 predicted binding domain was replaced by 
-melanocyte stimulating hormone ( MSH). A scheme representing the cloning strategy is 
shown in figure 9.  
AIP56-IL3: This construction was obtained by molecular cloning techniques using 
restriction enzymes for cleaving and inserting the coding sequence into the expression 
plasmid (figure 9A). The sequence encoding AIP561-373 was amplified from a plasmid 
containing the full length sequence of AIP56 (pETAIP56H+) already available [74] using 
primers AIP56FW9NdeI and AIP56RV7SacI (table 3). Primer AIP56FW9NdeI introduces 
to the N-terminal of AIP561-373 an NdeI restriction site, for cloning into pET28a(+) vector 
(Novagen) in frame with a 6x His-tag, followed by a TEV (Tobacco etch virus) cleavage 
site, for affinity purification and tag removal upon protein expression. Primer 
AIP56RV7SacI introduces a SacI restriction site at the C-terminal of AIP561-373, for ligation 
to IL-3. The sequence encoding IL-31-132 [97] was amplified from a plasmid containing 
mature human IL-3 cDNA (pLX304-IL3; Dana-Farber/Harvard Cancer Center DNA 
Resource Core, Harvard Medical School) using primers IL3FW1SacI and IL3RV1XhoI 
(table 3). Primer IL3FW1SacI introduces to the N-terminal of IL-31-132 a SacI restriction site 
for ligation to AIP561-373. Primer IL3RV1XhoI introduces to the C-terminal of IL-3 a XhoI 
restriction site for cloning into pET28a(+). After an initial denaturation step for 2 minutes 
(min) at 94°C, AIP561-373 and IL-31-132 were amplified by 30 cycles of denaturation at 94°C 
for 45 seconds (sec), annealing at 66°C for 30 sec and extension at 72°C for 30 sec or 20 
sec, respectively, followed by a final extension at 72°C for 5 min. The PCR-generated 
DNA fragments were extracted and purified from agarose gel using the GFX PCR DNA 
and Gel band purification Kit (GE 
cloned into the pGEM-T Easy vector (Promega) using T4 DNA Ligase (Promega), at 4ºC 
overnight. After amplification, the 1.1 kb AIP56 and 0.4 kb IL3 DNA fragments were 
excised from pGEM-T Easy vector with NdeI and SacI or SacI and XhoI, respectively. 
AIP561-373 was first ligated into pET28a(+), previously digested with NdeI and SacI, 
yielding the intermediate plasmid pETAIP561-373, to which IL-3 was ligated after digestion 
of  pETAIP561-373 with  SacI and XhoI, yielding the final plasmid pETAIP56-IL3. 
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AIP56 MSH: This construct was obtained by two consecutive PCR reactions (figure 9B). 
The sequence encoding AIP561-373 was amplified from pETAIP56H+ [74] with primers 
AIP56FW9NdeI and AIP56 MSHRV1 (table 3), the last one adding part of MSH to the C-
terminal end of AIP561-373, yielding the template to the second reaction. In the second 
reaction, primers AIP56FW9NdeI and AIP56 MSHRV2 (table 3) were used to obtain 
AIP56 MSH final sequence. Primer AIP56FW9NdeI introduces an NdeI restriction site in 
frame with a 6x His-tag, followed by a TEV cleavage site, as explained above. Primer 
AIP56 MSHRV2 introduces the remaining sequence of MSH followed by a XhoI 
restriction site, for cloning into pET28a(+). Both reactions were performed in the 
conditions as described above for AIP56-IL3, with exception of the annealing cycles: two 
initial cycles at 54°C and 30 subsequent cycles at 68°C. The 1.2 kb AIP56 MSH fragment 
was then extracted, purified, subcloned into the pGEM-T Easy vector and cloned into 
pET28a(+), as described for AIP56-IL3, but using NdeI and XhoI restriction enzymes, 
yielding plasmid pETAIP56 MSH. 
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Figure 9. Schematic representation of the cloning strategy. A) Strategy used to obtain the construct pETAIP56-IL3. This 
construction was obtained by molecular cloning techniques and restriction enzymes. PCR reaction was performed with the 
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respective primers for amplification of AIP56 and IL3 sequences. After, it was cloned into pGEM®-T Easy vector in the 
presence of T4 DNA Ligase. The AIP56 DNA fragments and IL3 DNA fragments were digested with respective restriction 
enzymes and ligated into pET28a previously cut with NdeI and XhoI. Induction of E.Coli with this plasmid resulted on 
production of chimeric AIP56-IL3 protein. B) Strategy used to obtain the construct pET28AIP56 MSH. Chimera AIP56 MSH 
was obtained by two consecutive PCR reactions. The first reaction yielded the template to the second reaction. PCR 
reaction was performed with the respective primers for obtain AIP56 MSH final sequence. After, it was cloned into pGEM®-
T Easy vector in the presence of T4 DNA Ligase. The AIP56 MSH DNA fragments were digested with NdeI and XhoI and 
cloning into pET28a previously cut with NdeI and XhoI. The primers used are indicated in respective figure.  
All PCR reactions were executed in a Thermo Scientific Piko Thermal Cycler 
(Thermo Scientific), following the manufacturer´s instructions. PCR amplification was 
performed with 20 ng of DNA template, 25 mM MgCl2, 10 mM deoxynucleotide 
triphosphates (dNTP) mix, 0.50 µg/mL of each primer, 1x PCR buffer (Promega) and 1 
unit of Taq DNAPolymerase (Promega).   
The plasmids obtained were produced in quantity and isolated from E. coli XL1 
Blue, grown in Lysogenic Broth (LB) [98] supplemented with 50 µg/mL kanamycin (Kan), 
using QIAprep Spin Miniprep kit (Qiagen) following the manufacturer´s instructions. 
Transformants with the desired construct were identified by PCR, using primers T7 
(forward) and T7 terminator (reverse) of pET28a(+), and sequencing. DNA concentration 
was determined by measuring the absorbance at 260nm (A260) using nanodrop. 
 
Table 3. Primers used in this work. 
 
1.1.2. Expression of chimeric AIP56-IL3 protein 
To produce AIP56-IL3 protein, different strategies were attempted (figure 10). 
Primer 
designation Nucleotide sequence 5´- 3´ Construct 
AIP56FW9NdeI ccccatatggagaatctttattttcagagcaacaacgataaaccagatgcaagc 
AIP56 MSH / 
AIP56-IL3 
AIP56RV7SacI gggagctcatatagaccggaattgagc AIP56-IL3 
IL3FW1SacI ccggagctcgctcccatgacccagacaacg AIP56-IL3 
IL3RV1XhoI gcgctcgagtcaaaagatcgcgaggctc AIP56-IL3 
AIP56 MSHRV1 cagcgaaaatgttccatggaataggaatatagaccggaattgagccc AIP56 MSH 
AIP56 MSHRV2 gcgctcgagtcacaccggtttgccccagcgaaaatgttccatgg AIP56 MSH 
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Figure 10. Flowchart of the strategy used in this work to obtain AIP56-IL3 recombinant protein. Protein production 
was attempted at different temperatures. However, it was always obtained in insoluble state. In order to solve this problem, 
different approaches were used: screening of different lysis buffers, using of vectors with solubility tags and refolding 
attempts. Highlighted in gray is the path from which it was possible to obtain protein to activity assays. 
For expression of AIP56-IL3 protein, E. coli BL21(DE3) competent cells were 
transformed with 3 ng of plasmid pETAIP56-IL3 by the heat and shock method. Briefly, 
DNA and competent cells were incubated on ice for 30 min. After, the cells were heat-
shocked for 90 seconds at 42°C, and immediately incubated on ice for 2 min. Afterwards, 
4 volumes of Super Optimal broth medium with catabolite repression (SOC) medium (2% 
Tryptone, 1% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 
20 mM Glucose) was added and incubated at 37ºC for 45 min, with shaking at 150 
rotations per minute (rpm). Finally, transformants were plated in LB-agar plates containing 
50 g/ml Kan and incubated overnight (ON) at 37ºC. A single colony was inoculated into 
LB medium supplemented with 50 Kan and incubated ON at 37°C with shaking (150 
rpm). The culture was then refreshed in fresh medium containing Kan, using 1:100 dilution 
38 FCUP/ICBAS 
Biotechnological and clinical potential of AIP56 toxin 
 
of the culture grown ON. When the culture reached an OD of 0.4 at 600 nm was incubated 
at different temperatures (17°C, 22°C, 30°C or 37°C), with shaking (150 rpm). 
Recombinant protein expression was induced by adding 0.5 mM Isopropyl -D-1-
thiogalactopyranoside (IPTG),  when the culture reached an OD of 0.6 at 600 nm, and 
protein expression evaluated at different temperatures (17°C, 22°C, 30°C or 37°C) and 
time-points (see respective figure in results section). Cells were then harvested by 
centrifugation at 4000 g for 30 min at 4°C (Beckman Avanti J-26 XP in an AJ81000 rotor), 
resuspended in lysis buffer (50 mM NaP, 500 mM NaCl, 200 µg/mL lysozyme, 1:500 
PMSF) on a ratio of 35 mL of lysis buffer per 1 L of culture and stored at -20°C. Induced 
bacterial cells were lysed by freeze/thaw, followed by sonication on ice (duty cicle- 
constant; output control- 5; 15x10 seconds) in the presence of 10 mM MgCl2 and 10 
µg/mL DNAse I. The soluble and insoluble fractions of the total lysates were separated by 
centrifugation at 21000 g for 15 min at 4°C and analyzed by SDS-PAGE followed by 
Coomassie-blue R-250 (Sigma Chemical) staining.  
As soluble AIP56-IL3 protein has not been obtained with any of the induction 
temperatures tested, a strategy based on adding different additives, described as 
promoting recombinant protein stability [99], to a base lysis buffer was attempted. The 
resulting lysis buffers are listed in table 4. 
After induction at 30°C, as described above, pellet from 1 mL of E. coli cell culture 
was resuspended in 450 µL of fresh lysis buffer and 50 µL of one of the eleven additives 
(table 4), previously prepared in 25 mM HEPES pH=7.0, at a final additive concentration 
indicated in table 4. Afterwards, sample was incubated on ice for 30 min, sonicated on ice 
(duty cicle- constant; output control- 4; 5x7 seconds) and the total cell lysate centrifuged 
at 4000 g for 30 min at 4°C. Then, supernatant and pellet were taken and stored as 
soluble and insoluble fractions, respectively. Both fractions were analyzed by Coomassie-
blue stained SDS-PAGE. 
Table 4. List of solubilization additives and buffer at final concentrations used in the assay to try rescuing soluble 
protein. 
Fresh lysis Buffer Solubilization Additives  
25 mM HEPES pH=7.0, 
 500 mM NaCl, 
 10 % w/v glycerol, 0.5 % 
CHAPS,  
10 mM MgCl2, 
0.1 % Lysozime,  
25 U/mL Benzonase 
0.75 M Trehalose 0.375 M L-Arginine  
1 M Xylitol  0.1 M Potassium citrate  
0.5 M Mannitol 0.1 M Dipotassium phosphate  
1 M Glycine betaine  0.01 M Sodium selenite  
1 M Trimethylamine N-Oxide 1 M 3-(1-Pyridinio)1-propane sulfonate 
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1.1.3. Purification of AIP56-IL3 
For obtaining soluble recombinant AIP56-IL3 from the insoluble fraction, a 
refolding protocol has been optimized from a protocol previously developed for obtaining a 
soluble truncated form of AIP56 [74]. The correct folding of AIP56-IL3 protein was then 
evaluated by (i) a catalytic assay that, by detecting catalytic activity, indicate the correct 
folding of the AIP56 domain, and (ii) an internalization assay that, by detecting receptor 
binding capacity, indicate the correct folding of the IL3 domain. 
1.1.3.1. Preparation of inclusion bodies  
After induction in BL21 E. coli at 30°C for 2 h, as described before, AIP56-IL3 
protein was produced as inclusion bodies. Thus, AIP56-IL3 inclusion bodies were isolated 
from E. coli cell pellets by sonicating twice in cold isolation buffer I (20 mM NaP pH 7.4, 
500 mM NaCl, 0.5 mM EDTA, 5 % Glycerol, 2 % Triton, 2 M Urea) followed by 
centrifugation at 22000 g for 15 min at 4°C, and once in cold isolation buffer II (20 mM 
NaP pH 7.4, 500 mM NaCl, 5 % Glycerol). After centrifugation, as above, pellets were 
stored at -20°C. 
1.1.3.2. Denaturation and reduction of inclusion bodies 
After thawing, inclusion bodies were solubilized in 8 M urea, 20 mM Tris-HCl pH 
8.0, 0.5 M NaCl, 1 mM 2-mercaptoethanol, in a ratio of 4 mL of buffer per 1 g of the 
original cell pellet, for 1 h at room temperature with gently stirring, followed by 
centrifugation at 21000 g for 15 min at 4°C. The supernatant fraction was withdrew and 
the denatured AIP56-IL3 protein adjusted to 0.2 mg/mL and subjected to refolding. 
Solubilized inclusion bodies were evaluated by Coomassie-blue stained SDS-PAGE. 
1.1.3.3. Refolding 
Three different strategies of refolding were attempted, as shown in figure 10 and 
described below.  
i)  Refolding by dialysis	
Denatured AIP56-IL3 was dialyzed (12-14000 molecular weight cut-off; dialysis 
Membrane Spectrumlabs) three times (6h + overnight + 6h) under stirring at 4°C against 
50 volumes of one of the buffers described in table 5.  
ii) Refolding by dilution 
Denatured AIP56-IL3 was added to one of the refolding buffers described in table 
5 by drop wise under rapid stirring at 4°C.   
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iii)  Refolding by dilution and dialysis 
Alternatively, denatured AIP56-IL3 was added to one of the refolding buffers 
described in table 5 by drop wise under rapid stirring at 4°C until urea concentration 
reached 1 M. Urea was then decreased to insignificant concentrations by performing an 
overnight dialysis at 4°C as described above. 
 
Table 5. Buffers used in the refolding protocol. 
Buffer refolding Buffer preparation 
PBS with 10 %Glycerol 10 mM NaH2PO4·H2O pH=7.2, 150 mM NaCl, 10 % Glycerol  
IL-3 [100] 0.5 M L-Arginine HCl, 100 mM Tris pH=8, 0.9 mM oxidized glutathione  
Tris-NaCl 20 mM Tris pH=8, 200 mM NaCl  
Tris-NaCl with 10% Glycerol  20 mM Tris pH=8, 200 mM NaCl, 10 % Glycerol  
 
1.1.4. Analysis and storage 
After refolding and clarification by centrifugation (21000 g for 5 min) the 
supernatant containing AIP56-IL3 were rapid freeze in liquid nitrogen and kept at -80ºC 
until use. Refolded AIP56-IL3 was analyzed by Coomassie-blue stained SDS-PAGE. 
Protein concentration was quantified by measuring absorbance at 280nm using nanodrop. 
1.2. Sea bass p65 (sbp65) Rel 35S-labeled protein 
For testing the AIP56-IL3 cleavage activity, the sea bass NF- B p65 Rel homology 
domain was synthetized in vitro using a rabbit reticulocyte lysate transcription/translation 
system (TNT T7 Quick Coupled Transcription/Translation systems kit, Promega, TM045) 
following the manufacturer´s instructions. Briefly, the reaction containing 1 µg of plasmid 
pET28a(+) encoding sbp65 Rel, TNT T7 Quick Master mix (containing Rabbit Reticulocyte 
Lysate) in the presence of Redivue
TM
 L-[35S]-Methionine (specific activity of N1000 
Ci/mmol) was incubated for 90 min at 30°C and stored at -80°C. The result of translation 
and radiolabel incorporation were evaluated by 14 % SDS-PAGE, transferred to 
nitrocellulose membrane (as described below) and revealed by autoradiography after 48 h 
film exposure. 
2. Cells  
AML cells. In this work, three human cells lines of Acute Myeloid Leukemia (AML) 
have been used: HL-60, NB-4 and KG-1 (Table 6).  
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Table 6. Classification of cell lines of acute myeloid leukemia (AML) used in this work, according to French-
American-British (FAB) classification system [101], and their relevant characteristics. 
Cell line FAB subtype Description FAB Origin Characteristics 
HL-60 M2 
Acute myeloblastic 
leukemia, with 
maturation 
1976,  
35 year old 
female [102] 
 Doubling time: 30h to 40h 
 Myeloblastic morphology 
 2 to 4 rounded nuclei [102] [103] 
NB-4 M3 
Acute promyelocytic 
leukemia (APL) 
1989,  
23 year old 
female [104] 
 Doubling time: 36h to 40h [104] 
 Round and polymorphic cells 
KG-1 M6 Erythroleukemia 
1977,  
59 year old male 
[103] 
 Doubling time: 40-50h 
 Morphology similar to dendritic myeloid 
cells [103] 
Human leukemia cell lines HL-60, NB-4 and KG-1 were kindly provided by Drª Paula 
Ludovico, University of Minho. All cells were grown in culture suspensions. NB-4 and HL-
60 cells were routinely cultured in RPMI 1640 medium supplemented with L-glutamine 
(Thermo Scientific, ref.SH30255.01) supplemented with 10 % heat inactivated fetal bovine 
serum (FBS) (Life Technologies, ref.10500064) and 1 % Penicillin/streptomycin 
(PenStrep; Lonza). KG-1 were cultured in the same culture conditions but supplemented 
with 20 % FBS. All cells were kept at 37°C in a 95 % air and 5 % CO2 humidified 
incubator. For these experiments, cells were used between 6 and 20 passages. 
3. Functional assays 
As the AIP56-IL3 chimera results from the fusion of two different and independent 
functional domains, a catalytic and putative translocation domain, provided by AIP56, and 
a receptor-binding domain, provided by IL3, assays for testing the catalytic and receptor 
binding activities, as well as intoxication, have been developed.  
3.1. Catalytic assays  
Using in vitro translated p65. In order to verify the catalytic activity of the AIP56 
domain, different concentrations (see respective figure in results section) of refolded 
AIP56-IL3 were incubated (2 h at 22°C) with in vitro Rabbit Reticulocyte Lysate translated 
35S-labeled sbp65Rel, in each respective refolding buffer (table 5), in a final volume 
adjusted to 20 µL. A similar reaction but without AIP56-IL3 was used as control. The 
cleavage of NF- B p65 was assessed by resolving in 14 % SDS-PAGE, transferred to 
nitrocellulose membrane (as described below) and revealed by autoradiography after 48h 
film exposure. 
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Using native p65. The catalytic activity of refolded AIP56-IL3 was also assessed 
towards native p65 obtained from HL-60 cell lysates. For this purpose, cell lysates were 
first obtained by incubating cells with lysis buffer (10 mM Tris-HCl pH 8.0, 0.5 % (v/v) 
Triton X-100, 150 mM NaCl and 10 % (v/v) glycerol) for 30 min on ice (30 µL per 2.0x106 
cells), briefly sonicated and centrifuged at 21000 g for 10 min at 4ºC. The soluble fraction 
was quickly stored at -80°C. 
For evaluating the AIP56-IL3 catalytic activity, aliquots of 2.0x105 cell lysates were 
incubated with AIP56-IL3 or recombinant AIP56 (positive control) in the concentration 
indicated (see respective figure in results section) for 2 h at 22°C, in a final volume of 30 
µL. Mock treated cell lysates were used as negative control. The cleavage of NF- B p65 
was assessed by Western blotting resolved in 10 % SDS-PAGE using a specific antibody 
to p65 (sc-372, Santa Cruz Biotechnology), as described below in section 4. 
3.2. Intoxication assays 
Using NF- B p65 cleavage as read out. AML cell suspensions were adjusted to 
a density of 1.0x106 cells, plated in wells of 24-well plates and incubated for different times 
(see respective figure in results section) at 37ºC (humid atmosphere with 5 % CO2) with 
AIP56-IL3 or recombinant AIP56, in concentration indicated (see respective figure in 
results section), in a final volume of 250 µL or 1 mL when incubated for more than 24 h. 
When specified, cells were pre-treated for 1 h and incubated in the presence of 20 µM 
Proteasome inhibitor MG132 (Enzo Life Science).  
After incubation, cells were centrifuged at 285 g for 5 min at 4ºC, washed once with PBS 
(10 mM NaH2PO4 H2O pH=7.2, 150 mM NaCl) and lysed with 60 µL of GLB (1x) and 100 
mM DTT. NF- B p65 cleavage was analyzed by Western blotting using a specific antibody 
to p65 (sc-372, Santa Cruz Biotechnology).  
Using apoptosis as read out. Apoptogenic activity was evaluated by the 
presence of typical morphological signs of apoptosis, namely, nuclear fragmentation, 
chromatin condensation and cell blebbing with formation of apoptotic bodies [105]. 
Apoptosis was assessed during different time points (2 h, 4 h, 6 h, 24 h, 48 h) after 
incubation at 37ºC with AIP56-IL3 or recombinant AIP56 at 70, 175 or 650 nM. AML cell 
suspensions were first fixed with 10 % of 37 % formaldehyde in absolute ethanol for 1 
min, washed once with water and stained with Hemacolor (Merck) as described in [71, 
74]. Morphology was evaluated by light microscopy. 
Using the LF-PA system from Bacillus anthracis as delivery system. As an 
alternative approach for evaluating the effect of cleaving NF- B p65 in AML cells, the 
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lethal factor-protective antigen (LF-PA) system from Bacillus anthracis was used for 
delivering the AIP56 N-terminal catalytic domain into the cells. For this purpose an 
[74] 
on the N-terminal portion of anthrax lethal factor (LF11-263) fused to AIP56 N-terminal 
catalytic domain (LF11-263 AIP561-261). The anthrax protective antigen (PA), the binding 
receptor for LF, was kindly provided by Professor Dr. Cesare Montecucco (Dipartimento di 
del CNR, Padova, Italy).  
Briefly, AML cells were plated at a density of 1.0x106/well of a 24-well plate and 
incubated simultaneously with  nM) and PA (10 nM) for 2 or 4 h at 37ºC in a 
final volume adjusted to 500 µL. After, cells were centrifuged at 285 g for 5 min at 4ºC, 
washed once with PBS and lysed with GLB (1x) and 100 mM DTT. NF- B p65 cleavage 
was evaluated by Western blotting, as described below in section 4, and apoptogenic 
activity analysed, after 4h incubation, as described above. This experiment was repeated 
but comparing to higher concentration of 40 nM) and PA (20 nM) and extending 
to 6 h incubation. 
3.3.  Internalization assays 
For detection of AIP56-IL3 within cells an internalization assay has been 
performed. For this, cells were plated on 24-well plates at a density of 5x105 cells/well, 
pulsed with 200 nM of AIP56-IL3 protein or recombinant AIP56 and incubated for 30 min 
on ice, for allowing the binding of the toxins to its cell surface receptor. After, cells were 
transferred to 37ºC and incubated for 10 min for allowing internalization of receptor-bound 
toxin into cells by activation of the endocytic machinery. The cells were then transferred 
again to ice for 5 min in order to block protein degradation, recycling and/or other cellular 
activities. After, cells were washed twice with ice-cold PBS, to remove unbound toxin, and 
incubated for 10 min on ice with 125 µg/mL Pronase E from Streptomyces griseus (Sigma 
Aldrich P5147) diluted in PBS (final volume of 250 µL), in order to eliminate extracellular 
cell-  Next, Pronase E was inactivated with 1 mL of 250 µg/mL 
PMSF in PBS and washed twice with ice cold PBS. Cells not treated with Pronase E were 
used as control. 
In order to check the efficiency of Pronase E in removing the extracellular cell-
bound toxin a similar protocol was applied to cells where the 10 min internalization step at 
37ºC has been replaced by 10 min incubation on ice for preventing internalization. 
Untreated, mock-treated cells and cells treated with protein but without incubation with 
pronase E were used as controls. Finally, cells were collected either by centrifugation or 
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by scrapping from the wells, lysed with 60 µL GLB (1x) and 100 mM DTT, and AIP56 
detected by Western blotting using a rabbit anti-AIP56 antibody [70], as described below 
in section 4. 
4. Miscellaneous 
4.1. SDS-Page and Western Blotting  
Proteins were mixed with Gel Loading Buffer (GLB; 50 mM Tris-HCl pH 8.8, 2% 
SDS, 10 % glycerol, 0.017 % bromophenol blue, 2 mM EDTA pH 8.8, 100 mM DTT) and 
denatured by heating at 95ºC for 5 min. Samples were run on a reducing sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and either stained with 
Coomassie Blue R-250 (Sigma Chemical) or transferred to nitrocellulose membrane in 
transfer buffer (25 mM Tris-Base, 192 mM glycine, 20 % methanol, pH 8.3), for 1 h at 19 
V.  For controlling transfer efficiency, protein loading and locating the molecular weight 
markers, membranes were stained with Ponceau S (Sigma) and scanned. Membranes 
were then blocked with Tris-Buffered saline (TBS) with 0.01 % tween-20 (Sigma) (T-TBS) 
containing 5 % of non-fat dry milk at room temperature for 1 h or overnight at 4°C, to 
saturate (blocking) nonspecific binding sites and prevent non-specific binding of both 
primary and secondary antibodies. After, membranes were incubated for 1 h at room 
temperature (RT) with shaking with the corresponding primary antibody: anti-human NF-
B p65 C-terminal domain (c-20) rabbit polyclonal IgG antibody (sc-372, Santa Cruz 
Biotechnology; 1:3000), rabbit anti-AIP56 [70] (2nd bleed, 1:5000) or anti-GAPDH (6C5) 
mouse monoclonal antibody (sc-32233, Santa Cruz Biotechnology; 1:20000), all diluted in 
blocking solution. Then, membranes were washed three times (5 min each) with T-TBS at 
RT and incubated with goat anti-rabbit alkaline phosphatase conjugated secondary 
antibody (A9919, Sigma Aldrich; 1:30000) or goat anti-mouse alkaline phosphatase 
conjugated secondary antibody (A2429, Sigma Aldrich; 1:10000) in T-TBS. The reaction 
was developed using 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium 
(BCIP/NBT, Promega).   
4.2. Biochemical parameters  
Theoretical molecular weight was obtained using the ProtParam tool 
(http://web.expasy.org/protparam/). 
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4.3. Purity of the protein 
The purity of the proteins was determined by densitometry analysis of Coomassie Blue-
stained gels using Fiji software, and results expressed as density of the recombinant 
protein band relative to total density of the lane. 
4.4. Protein quantification 
Concentration of recombinant protein was determined by measuring absorbance at 280 
nm using nanodrop. 
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1. AIP56-IL3 was successfully cloned  
To test the concept of using AIP56 fused to receptor-ligand moieties for targeting 
specific cells, two recombinant proteins were engineered, by replacement of the putative 
receptor binding domain of AIP56 (G374 to N497) either by -melanocyte stimulating 
hormone (-MSH) or Interleukin-3 (IL-3), and produced. The constructs consist on the first 
373 amino acids of AIP56, including its catalytic domain, fused to -MSH or to human IL-
3, the later via a glutamic acid (E)-leucine (L) linker resulting from the SacI restriction site 
used to fuse AIP56 to IL-3.  
For purification purposes, a 6xHis purification tag followed by a TEV cleavage site were 
added to the N-terminus, to avoid putative interferences in the cell binding ability assured 
by the C-terminal fused moiety, and for removing the purification tag. Constructs were 
inserted into pET28a(+), rendering pET28AIP56MSH and pET28AIP56-IL3 expression 
vectors. Cloning was performed using molecular biology techniques. The correct 
sequences of the constructs were verified by sequencing analysis. An error (nucleotide 
deletion) has been introduced in the sequence of AIP56MSH and, therefore, 
recombinant protein production and functional testing were only performed for AIP56-IL3 
(see annex figure 1S). Constructs are schematically represented and compared with full 
length AIP56 in figure 11. 
 
Figure 11. Schematic representation of chimeric proteins used in this work. Full length AIP56 (used as control in each 
experience), AIP56 fused with interleukin-3 (AIP56-IL3) and AIP56 fused with -Melanocyte Stimulating Hormone 
(AIP56MSH) are depicted. 
2. AIP56-IL3 chimera is obtained in insoluble state 
BL21 (DE3) E. coli were transformed with pET28AIP56-IL3. Production of 
recombinant protein was then attempted by screening and optimization of known 
protocols. Protein induction and solubility at different temperatures was assessed and 
monitored at different time points by SDS-PAGE.  
Analysis of the SDS-PAGE gel showed that the recombinant protein was successfully 
obtained in three (22ºC, 30ºC and 37ºC) of four temperature tested (figure 12A); however, 
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they have been all obtained in insoluble state (figure 12B). Despite several attempts, 
induction did not occur at 17ºC. The induction temperature for posterior tests was 30ºC. 
The recombinant protein has a predictive molecular weight of 60.4 kDa.  
 
Figure 12. SDS-PAGE gels representing the induction temperature and solubility tests for AIP56-IL3. Culture of E. 
coli BL21(DE3) competent cells transformed with plasmid pETAIP56-IL3 were grown at indicated temperature. When culture 
reached an OD of 0.6 at 600 nm, recombinant protein expression was induced with 0.5 mM IPTG and incubated with 
shaking (150 rpm). A) The cells were harvested by centrifugation and the fraction of total lysates analyzed. Coomassie Blue 
staining of a 12 % acrylamide SDS-PAGE showing the induction of recombinant protein at different time points. The 
expected molecular weight of the recombinant protein (~60.4 kDa) is indicated by an arrow. Molecular weight standards with 
the corresponding weights are indicated. B) Coomassie Blue staining of a 12 % acrylamide SDS-PAGE showing the soluble 
(supernatant) and insoluble (pellet) fractions of induced protein. After induction and incubation for the indicated time, cells 
were harvested by centrifugation, resuspended in lysis buffer and stored at -20°C. Cells were additionally lysed by 
freezing/thawing, followed by sonication on ice. Soluble and insoluble fractions were separated by centrifugation and 
analyzed by Coomassie-blue stained SDS-PAGE. The expected protein band at ~60.4 kDa is indicated by an arrow. 
A 
B 
 
FCUP/ICBAS 
Biotechnological and clinical potential of AIP56 toxin 
51 
 
 
In order to obtain soluble protein, a new screening was performed using different 
lysis buffers, in which eleven additives, described as recombinant protein stability 
promotors during cell lysis [99], have been selectively added. Cells were induced for 2 
hours at 30 ºC and lysed with fresh lysis buffer (see material and methods section) with 
one of the mentioned additives (figure 13). Analysis by Coomassie-stained SDS-PAGE 
gel revealed that, for all conditions, recombinant proteins were in the insoluble fraction, 
precluding the use of the above mentioned additives for obtaining soluble AIP56-IL3 
(figure 13). 
  
Figure 13. SDS-PAGE showing results from the lysis buffer screening. In each condition, cell culture pellets were lysed 
using a base lysis buffer( fresh lysis buffer) to which different additives have been selectively added (indicated on top of the 
gel). Subsequently, cells were sonicated and centrifuged, and the insoluble and soluble fractions analyzed by Coomassie 
Blue stained 12 % acrylamide SDS-PAGE. Arrows indicate the recombinant protein. 
Therefore, two additional approaches were attempted:  (i) cloning the chimeric proteins 
in vectors with solubility tags and (ii) refolding the insoluble protein previously obtained. 
The first strategy was performed by an undergraduate student and is not reported in this 
thesis.   
3. Refolded AIP56-IL3 is catalytically active 
Insoluble AIP56-IL3 was extracted from E. coli BL21 (DE3) cultures induced at 
30°C for 2 hours. The general strategy used to recover active protein from inclusion 
bodies involved three main steps: (i) isolation and wash of inclusion bodies; (ii) 
solubilization of aggregated protein with 8 M urea (solubilizing agent); and (iii) refolding. 
The first two steps were performed based on an already established protocol. For the 
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refolding step, screening of different parameters, including refolding buffer and 
techniques, were attempted (table 7 and figure 14).  
  Table 7. Refolding parameters tested in this work. 
 
The choice of refolding buffers was based on prior experience with refolding of 
other AIP56-derived proteins [74]. In addition, the IL-3 buffer, reported in the literature and 
shown to successfully refold other chimeras containing fused IL-3 [100, 106], was 
included. However, the chelate constituent EDTA (Ethylenediaminetetraacetic acid) 
present in this buffer was removed, to avoid interference with the metalloprotease activity 
of AIP56.  
 
Figure 14. Combination of different refolding techniques with distinct refolding buffers tested. The initial step of the 
refolding process was done by dilution or dialysis to each respective buffer. For dilution, proteins were either diluted until 
removal of the denaturing agent or, alternatively, diluted until 1 M of denaturing agent has been reached followed by dialysis 
against the indicated buffer. For dialysis, proteins were either dialyzed against each respective buffer or, in the case of IL3 
buffer, exchanged by dialysis to Tris-NaCl.  
The purification of inclusion bodies resulted in a relatively high amount of insoluble 
AIP56-IL3 with low levels of other unspecific proteins. Since the solubilisation of this 
fraction yielded AIP56-IL3 with >80% purity (not shown), the refolding protocols were 
subsequently performed without further purification by nickel-affinity chromatography 
using the N-terminal 6xHis-tag. 
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Refolding efficiency, under the selected conditions, was done by analyzing 
equivalent volumes of soluble and insoluble fractions by SDS-PAGE (figure 15A and 
figure 3S in Annex). The best strategy was selected considering that recovery of protein in 
the soluble fraction is an indicative of a successful refolding. Direct dialysis against Tris-
NaCl or IL-3 buffer as well as dilution followed by dialysis against PBS with 10 % glycerol 
(Figure 3S) seem to gather the best conditions for refolding this chimera. Due to its higher 
complexity (multi steps) without significant gain, the condition involving dilution and 
dialysis against PBS with 10 % glycerol was rejected. 
The AIP56-IL3 protein encompasses the catalytic domain of the AIP56 toxin, which 
acts by cleavage of NF-κB p65 [107]. Therefore, the proteolytic activity of AIP56-IL3 
towards p65 was evaluated, in order to confirm the correct folding of the AIP56 domain. 
For this purpose, refolded AIP56-IL3, after dialysis against Tris-NaCl or IL3 buffer, was 
incubated with 
35
S-labeled sbp65Rel, and p65 cleavage assessed by autoradiography. 
AIP56 full length was used as control.  
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Figure 15. Analysis of the refolding process. A) Denatured AIP56-IL3 was dialyzed against Tris-NaCl ( indicated in figure 
as: AIP56-IL3 in Tris-NaCl) or IL3 Buffer (indicated in figure as: AIP56-IL3 in IL3 buf.). The insoluble and soluble fraction of 
refolded AIP56-IL3 was analyzed by Coomassie-blue stained 12 % acrylamide SDS-PAGE. The overexpressed protein 
(~60.4 kDa) is indicated by an arrow. B) Catalytic activity of AIP56-IL3. Incubation of in vitro translated 35S-labeled sbp65Rel 
with AIP56 in Tris-NaCl and AIP56-IL3 dialyzed against Tris-NaCl (AIP56-IL3 in Tris-NaCl) resulted in p65 cleavage. When 
AIP56-IL3 was dialyzed against IL3 Buffer (AIP56-IL3 in IL3 Buf) no cleavage was observed even at 100 mM. The mix was 
incubated for 2 hours at 22°C with 10 nM or 100 nM of the indicated protein and p65 cleavage assessed by 
autoradiography. The position of full length (p65) and cleaved (cl-p65) p65 are indicated. The corresponding Ponceau 
staining membranes are shown below. C) Inhibitory effect of IL3 buffer. The IL3 buffer from refolding of AIP56-IL3 was 
exchanged by dialysis to Tris-NaCl (AIP56-IL3 in IL3 Buf/Tris-NaCl) and its cleavage activity compared to wild type AIP56 
(wt) in Tris/NaCl and AIP56-IL3 refolded against IL3 buffer (AIP56-IL3 in IL3 Buf) in the presence of the indicated incubating 
buffer. The values are indicated in microliters (µL). 
As expected, incubation of 
35
S-labelled sbp65Rel with AIP56 (in Tris-NaCl) 
resulted in p65 cleavage (figure 15B). The same result was observed for AIP56-IL3 when 
refolding was performed by dialysis against Tris-NaCl. However, no cleavage was 
observed when refolding of AIP56-IL3 was performed by dialysis against IL3 buffer or 
when IL3 buffer was added to AIP56 as control reaction, suggesting that this buffer is 
inhibiting AIP56’s enzymatic activity. The inhibitory effect of the IL3 buffer was confirmed, 
as exchanging the IL3 buffer to Tris-NaCl by dialysis resulted in p65 cleavage by AIP56-
IL3, but only when Tris-NaCl is used as incubating buffer (figure 15C, lane 9). The 
cleavage activity of wild type AIP56 is also inhibited when IL3 buffer is used as incubating 
buffer (figure 15C, lane 5). Moreover, when the cleavage activity of wild type AIP56 is 
tested by mixing IL3 buffer with Tris-NaCl buffer (figure 15C, lane 7 and 8) in the same 
proportion (4 µL IL3 buffer:12,99 µL Tris-NaCl or 8 µL IL3 buffer:8,99 µL Tris-NaCl) as the 
one used for testing the cleavage activity of AIP56-IL3, refolded in IL3 buffer (4 µl or 8 µl), 
in Tris-NaCl (15,5 µL or 11,5 µL ) (figure 15C, lane 3 and 6, respectively), its cleavage 
activity is reduced, when compared with the AIP56(wt) cleavage activity tested with Tris-
NaCl only. This suggests that the AIP56-IL3 preparation may not be as stable as that of 
wild type AIP56 or refolding of the AIP56 domain in the AIP56-IL3 chimera is not 
absolutely resembling the one of wild type toxin. 
Cleavage of NF-κB p65 by the chimeric protein (AIP56-IL3 refolded against Tris-
NaCl) was also evaluated using AML cell lysates (figure 16), therefore, directly testing 
cleavage activity on cellular p65. Three incubation buffers were first tested: Tris-NaCl 
buffer, lysis buffer and IL-3 buffer (figure 16A). These results are in agreement with those 
described above for in vitro translated p65, given that p65 cleavage was detected only 
when Tris-NaCl was part of the incubation buffers, and inhibited when IL3 buffer is used. 
However, enzymatic activity was greatly reduced in the Tris-NaCl buffer when compared 
to the activity in lysis buffer, in which triton and glycerol are present. Therefore, 
experiments for testing the effect of different incubating buffers, containing triton and/or 
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glycerol, on the enzymatic activity of AIP56-IL3 in AML cell lysates were performed (figure 
16B). For this purpose, triton and/or glycerol were added to 20mM Tris-200 mM NaCl or 
10mM Tris-150 mM NaCl, until a similar condition to that of lysis buffer has been reached. 
However, in none of the conditions the efficiency of p65 cleavage by AIP56-IL3 was 
compared to that observed when lysis buffer was used. These results suggested that 
recombinant AIP56-IL3 is not as stable as wild type AIP56 because, when the 
components of the incubating buffer are slightly changed, p65 cleavage by AIP56-IL3 is 
strongly compromised when compared to that of wild type AIP56 (figure 16B). 
 
 
Figure 16. Cleavage activity on cellular NF-κB p65. The lysates were incubated for 2 hours at 22°C with indicated protein 
and cleavage assessed by Western blotting  A) Incubation of AML cell lysates with 10 nM or 100 nM of AIP56 or AIP56-IL3 
refolded by dialysis against Tris-NaCl in the presence of the indicated incubation buffers. B) Incubation of AML cell lysates 
A 
B 
P
on
ce
au
 S
.  
P
on
ce
au
 S
.  
56 FCUP/ICBAS 
Biotechnological and clinical potential of AIP56 toxin 
 
with 100 nM of AIP56 or AIP56-IL3 refolded by dialysis against Tris-NaCl, in the presence of the indicated incubation 
buffers. Incubation of AML cell lysates without protein and with indicated buffer (Mock) was used as control. The 
corresponding Ponceau is shown.  
Lysis buffer: 10 mM Tris-HCl pH 8.0, 0.5 % (v/v) Triton X-100, 150 mM NaCl and 10 % (v/v) glycerol. The position of the full 
length (p65) and cleaved p65 (cl-p65) are indicated. 
 
Considering that direct refolding by dialysis against Tris-NaCl was the faster and 
cheaper process this condition was chosen for proceeding to large-scale production of 
active AIP56-IL3. However, the refolding process was further improved by testing the 
initial concentration of insoluble protein that would render the best recovering of soluble 
protein. For this purpose, different initial protein concentration was tested, ranging from 
0.1 to 1 mg/mL. Results showed that the best yield (figure 17A) and p65 cleavage 
efficiency (Fig. 17B) was obtained when the starting concentration of unfolded AIP56-IL3 
was 0.2 mg/mL. 
The soluble refolded AIP56-IL3 had a purity >81% (figure 2S in Annex). Functional 
assays were performed with no further purification procedures. 
 
 
Figure 17. Improvement of the refolding process by dialysis against Tris-NaCl. A) Different concentrations of unfolded 
AIP56-IL3 (top of the gel) were dialyzed against Tris-NaCl. Insoluble and soluble fractions were analyzed by Coomassie-
blue stained 12 % acrylamide SDS-PAGE. The best condition for obtaining the higher proportion of soluble AIP56-IL3 is 
indicated by an arrow. B) Catalytic activity of AIP56-IL3. The p65 cleavage activity from AIP56-IL3, resulting from the 
refolding from different initial protein concentrations (indicated in figure), was analyzed in vitro by incubation with translated 
35S-labeled sbp65Rel. Wild type AIP56 was used as control. The mixture was incubated for 2 hours at 22°C with 20 nM of 
the indicated protein and p65 cleavage assessed by autoradiography. Position of full length (p65) and cleaved p65 (cl-p65) 
are indicated. The corresponding membrane stained with Ponceau is shown below. 
In conclusion, the first part of this work, which included the production of chimeric 
proteins, was successfully achieved for AIP56-IL3. As AIP56-IL3 was recovered in 
insoluble state, refolding processes were tested, with two of them, direct dialysis against 
Tris-NaCl and dialysis against IL3 buffer followed by buffer exchange by dialysis against 
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Tris-NaCl, resulting in successful recovering of soluble and active chimeric protein. Taking 
into account that the chimera has two independent domains, the catalytic and the receptor 
binding, it is still necessary to validate the correct folding of the IL3 cell receptor-binding 
domain, used in this chimera. For this purpose, intoxication and internalization assays 
were developed, as shown below in the second part of this work. 
4. AIP56-IL3 did not cleave p65 in AML cell lines  
To elucidate whether replacement of AIP56’s putative receptor binding domain by 
particular moieties leads to toxicity in specific cell types, cleavage of p65 was used as 
readout for the arrival of the chimera or chimera’s catalytic domain into the cytosolic 
compartment. Induction of apoptosis was also evaluated, as cleavage of p65 by AIP56 
was shown to trigger apoptotic cell death in macrophages.  
Given that several cancer cells possess their own membrane signature and often 
some of those molecules are overexpressed, the biological signal can be easily amplified 
and these characteristics harnessed to direct molecules of interest. Taking into account 
that AML cells overexpress IL-3 receptor at cell surface [108] and the binding of IL3 to its 
receptor causes rapid receptor-mediated endocytosis [68], the detection of proteolytic 
activity towards p65, located in the cytosol, will indicate the internalization and successful 
delivery of AIP56-IL3 and/or its catalytic domain into AML cell cytosol. 
For this purpose, and given that different cell lines express different receptor 
levels, three AML cell lines were used. Cells were incubated continuously with AIP56 or 
AIP56-IL3 proteins, at different times and p65 proteolysis assessed by Western blotting. 
Different doses were tested, from doses enough to observe depletion of p65 and death in 
fish macrophages [74] to higher doses, to have into account possible lower catalytic 
activity of the refolded chimera when compared to wild type toxin. Untreated and mock-
treated cells were used as control.  
As shown in figure 18A, no changes in p65 level was observed upon incubation 
with either protein at any of the doses and incubating times tested, independently of the 
cell line used. Consequently, no apoptosis signs were also observed (not shown). Given 
the constitutively active expression of NF-κB p65 in blasts of acute myeloid leukemia [109, 
110], it could have happened that decreasing of p65 band due to cleavage by AIP56 
and/or AIP56-IL3 was not observed because of the p65 overexpression in these cells. The 
absence of p65-cleavage fragment (cl-p65) could have also been due to its degradation 
by the proteasome machinery, as already shown to occur when macrophages are 
incubated with AIP56 (in press). To discard the above assumptions, KG-1 cells were 
incubated with high doses of AIP56 and AIP56-IL3 in the presence of the proteasomal 
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inhibitor MG132. However, no cl-p65 was detected, confirming that indeed p65 was not 
cleaved by any of the proteins tested (figure 18B).  
 
 
Figure 18. Catalytic activity of AIP56-IL3 in AML cells. A) NF-κB p65 was not cleaved by AIP56-IL3. Different AML cell 
lines (top of the figure) were incubated with AIP56-IL3 for the indicated time and p65 cleavage detected by Western blotting. 
Protein concentrations are indicated in each respective figure. Untreated cells, mock treated cells and cells incubated with 
AIP56 (in some experiments) were used as controls. B) Cells were incubated with high doses of AIP56 and AIP56-IL3 in the 
presence of the proteasomal inhibitor MG132. 
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These results suggest that the catalytic portion of both AIP56 and AIP56-IL3 was 
unable to reach the cytosol. Therefore, internalization assays were attempted to check 
whether the lack of p65 cleavage was due to low number or lack of cell associated 
specific receptor, for AIP56, or incorrect folding of IL3 domain, with concomitant inhibition 
of binding, or inhibition of translocation of the catalytic domain, in AIP56-IL3. 
However, although several attempts have been done to properly develop a 
suitable protocol for testing internalization of AIP56-IL3 in AML cells, no p65 cleavage was 
observed (see annex section figure 4S). Nevertheless, the results obtained may have 
been compromised, mostly by lacking of a proper antibody for detecting AIP56-IL3. 
Actually, AIP56 internalization assays in macrophages have been previously performed 
with success, but the AIP56 used on those tests contained a fused V5 tag that allowed the 
use of an anti-V5 antibody for detecting internalized AIP56. Lack of a good antibody 
becomes even more detrimental due to the loss of cells in conditions treated with pronase, 
which use is essential in internalization tests as it removes membrane bound toxin, 
therefore, allowing detection of only internalized toxin.  
5. Delivered of AIP56 catalytic domain into cell cytosol by the 
LF/PA delivery system resulted in p65 cleavage but not apoptosis 
Given that the internalization assays precluded any conclusion on whether AIP56-
IL3 toxicity in AML cells failed due to improper folding of the IL3 domain within AIP56-IL3, 
therefore inhibiting binding of AIP56-IL3 to AML cells, or due to inability to translocate the 
enzymatic domain into the cell cytosol, an alternative approach for delivering the AIP56 
catalytic domain into the cell cytosol of AML cells was considered. Knowing the success of 
anthrax LF/PA system in delivering the catalytic domain of several toxins, such as 
diphtheria, shiga and pseudomonas [74, 111-113], and that this system has been used 
successfully for delivering the catalytic domain of AIP56 into the cell cytosol of fish and 
mouse macrophages [74], it become an obvious approach for delivering AIP56 catalytic 
domain into AML cells and evaluating its performance in inducing apoptosis.  
In this work, an AIP56 catalytic domain-LF chimeric protein [74], consisting on LF 
N-terminal region (LFN) fused with AIP56’s N-terminal enzymatic region (LF11-263∙AIP561-
261), was used together with PA. In order to evaluate the delivery of AIP56 into the cytosol 
of AML cells, cleavage of NF-κB p65 was assessed by Western blotting after incubation of 
AML cells with LF-AIP56 in the presence of PA. Apoptosis was evaluated by morphologic 
analysis. 
Preliminary results (figure 19), showed cleavage of p65 in cells incubated with 
LF11-263∙AIP561-261, although without depletion, indicating efficient delivery of AIP56 
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catalytic domain into these cells. In opposition, in cells incubated with AIP56 or in control 
conditions no cleavage was observed. Nevertheless, the observed level of p65 cleavage 
did not result in apoptogenic activity (not shown). 
 
Figure 19. Delivery of the AIP56 N-terminal catalytic region into the AML cell cytosol, using the Bacilus anthracis 
LF/PA system. Different AML cell lines (indicated on top of the figure) were incubated for 2 or 4 h at 37°C with 20 nM LF11-
263.AIP561-261 in the presence of 10 nM PA or 100 nM (5.6 µg/mL) AIP56. Mock treated cells with Tris-NaCl were used as 
control. Cleavage of the NF-κB p65 was detected by Western blotting. The position of the full length (p65) and cleaved p65 
(cl-p65) are indicated. 
 
The low p65 cleavage may have been due to loss of some activity of PA because it 
was not freshly produced for this experiment and have suffered successive cycles of 
freezing and thawing. This has been supported by using a freshly made batch of PA in the 
second experiment, using HL-60 cells, because cleavage of p65 was significantly 
increased (figure 20). However, apoptosis was still not induced. 
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Figure20. Delivery of the AIP56 N-terminal catalytic region into the AML cell cytosol, using the Bacilus anthracis 
LF/PA system, with new batch of PA. Hl-60 cell line was incubated for 2, 4 or 6 h at 37°C with 20 nM LF11-263.AIP561-261 in 
the presence of 10 nM PA ( indicated as 20/10) or 40 nM LF11-263.AIP561-261 in the presence of 20 nM PA ( indicated as 
40/20). Mock treated cells with Tris-NaCl  and cells incubated with LF or PA were used as control. Cleavage of the NF-κB 
p65 was detected by Western blotting. The position of the full length (p65) and cleaved p65 (cl-p65) are indicated. 
Membrane was reprobed with an anti-GAPDH antibody (used as protein loading). 
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Over time and following research progression, AB toxins have revealed valuable 
tools in the study of fundamental cellular functions and are now being investigated for 
potential applications in the clinical treatment of human diseases like cancer and a variety 
of autoimmune disorders. Examples of these toxins most often used as tools include 
diphtheria, anthrax toxins and PE [64]. 
To this end, toxin-based cell delivery systems avail the structure-function of AB 
toxins, which are divided into distinct domains, as well as its extremely potency, leading to 
the use of these toxins as vectors to bring other molecules into cells. The common 
strategy to design these chimeric proteins involves the combination of the targeting moiety 
that confers target specificity to the chimeric protein and tropism to specific cells, with a 
potent effector molecule, the toxin. Thus, this fusion occurs between two independent 
functional domains, which are, biological and individually, often found in distinct biological 
systems, performing their activities under specific requirements. One example of this 
approach is the chimeric protein constructed and produced in this work. This chimera is 
composed of human IL-3, acting as the targeting moiety, linked to the catalytic domain of 
AIP56 toxin via molecular biology strategies. AIP56 is produced by Photobacterium 
damselae piscicida, a gram-negative bacterium [70], which infection affects several salt 
warm water fish species, including sea bass. AIP56 shares the same salt requirements of 
its producing bacterium [114] and the stability of this toxin is promoted by halophilic 
environments. 
The expression of the majority of heterologous proteins is performed in E. Coli, a 
widely used system that lacks post-translational modification machinery. This fact, 
alongside with the distinct nature and stability requirements of the moieties, present the 
most difficult challenges to modern biotechnology for production of soluble and stable 
chimeric proteins. However, several efforts have been attempted, given that the 
expression in soluble conditions is paramount for the expressed protein to be biologically 
active [115]. Although a number of general and protein-specific techniques are available, 
their effectiveness varies widely. Several strategies to try to identify experimental set-ups 
leading to the production of soluble proteins include molecular biology techniques, as well 
as manipulation of the culture environment [116]. In terms of bacterial expression, the 
system used, bacterial strain, the use of specific additives, concentration of IPTG or 
temperature are some of the conditions commonly tested [116, 117].  
In this work, the choice of the expression conditions in E. Coli for obtaining soluble 
protein was based in previous experience in successful production of soluble AIP56.  
Nevertheless, regarding the different nature of this chimera, an initial screening of 
induction temperatures was performed. In all the conditions tested only insoluble protein 
was obtained. Given the lower production at 22ºC and the fact that the production at 30 
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and 37ºC was not significant different, induction at the intermediate temperature of 30ºC 
was selected to proceed.  
As a way to find a solution for the solubility issue found earlier, the second attempt 
to recover soluble protein was made by a lysis buffer screening. In this rescue method, it 
is hypothesized that a significant fraction of protein is not found in inclusion bodies but 
rather expressed as soluble protein aggregate after lysis [99, 118]. Thus, the addition of 
specific additives, that have been shown to increase the stability of proteins in vivo, during 
cell lysis, can prevent the partially unfolded protein aggregation from occurring or leading 
to the properly folded and non-aggregated state, by acting as chemical chaperones, and 
consequently aiding in its recovery in the soluble fraction [99, 119]. Overall, some 
stabilizing properties include: reduction of protein-protein interaction, stabilization of intra-
molecular bond or thermally stabilization of proteins [99, 120]. Here, eleven additives 
known by these properties were tested. However, all of them failed in preventing protein 
aggregation. Even though several general and protein-specific methods are available for 
obtaining solubility of expressed proteins in E. coli, the proteins, in this system, are often 
expressed as insoluble aggregates of folding intermediates known as inclusion bodies 
(IBs) [115]. For AIP56-IL3 chimera, the presence of two disulfide bonds in its structure [74, 
121], can contribute widely to the production of insoluble protein observed, due to the 
bacterial cytoplasmic reducing environment, which is unfavorable for the formation of 
disulfide bonds, leading often to aggregation of unfolded proteins into IBs [122, 123]. 
Accordingly, chimeras composed of diphtheria toxin fused IL-3, reported in literature, are 
obtained by refolding process [17, 97, 100, 106]. Considering this problem, modification of 
the cytoplasmic reducing environment and/or co-expression of protein chaperones could 
be used as solving strategies [122, 124].  
Other current protocols are available that describe various strategies for the 
conversion of inactive protein, expressed as insoluble inclusion bodies, into a soluble and 
active fraction [125]. A common strategy used consists in the solubilization and refolding 
of inclusion body into an active conformation. However, although considerable progress in 
the last years has been made for efficient refolding of proteins, this process is not 
straightforward because specific folding conditions differ greatly from protein to protein 
[115]. It is not possible to predict which compound will facilitate folding of a particular 
protein, or whether more than one is required for this process [116], requiring an extensive 
trial-and-error approach. In case of chimeric proteins, an additive can promote the 
refolding of one moiety but not the other, representing an instability factor, affecting the 
overall stability of the protein and therefore its functional activity. The major drawbacks 
during the refolding are the reduced recovery, usually lower than 10% [115], the 
requirement for rigorous optimization of refolding conditions for each target protein, and 
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the possibility that the re-solubilization procedure could affect the activity of the refolded 
protein [125]. Thus, in many cases it may be difficult and expensive to obtain a soluble 
functional protein. This way, exploiting the production of recombinant proteins in a soluble 
form using other methodologies, other than in vitro refolding procedures, still remains a 
preferable alternative [116, 125]. Nevertheless, this may be the only way of obtaining the 
protein of interest in the biologically active state. 
Given that we were confronted by the solubility problem, the refolding approach 
was performed in an attempt to obtain active protein. As mentioned earlier, this process is 
characterized by a trial-and-error approach and must be done on a case-by case basis. In 
the work here presented, different refolding buffers as well as refolding methodologies 
were tested. The starting point for this test was based in previous successful experience 
in obtaining soluble AIP56 and AIP56 derivatives (e.g., mutants and truncated forms) 
using this methodology. Combinations of techniques as well as refolding buffers were 
tested. Thus, the AIP56-IL3 was produced and subjected to refolding by dialysis against 
Tris-NaCl. The correct folding of the AIP56 domain in this chimera was demonstrated by 
the ability of AIP56-IL3 to cleave both 35S-labelled sb p65Rel domain and p65 in AML cell 
lysates, although the weaker cleavage activity of AIP56-IL3 towards p65 in AML cell 
lysates, when compared to that of wild type AIP56, suggest that stability of the 
recombinant chimera was not yet completely achieved.   
AIP56 is classified as a single chain AB toxin. Its known main action is against fish 
neutrophils and macrophages by cleavage of the p65 subunit of NF- B within its Rel 
homology domain, triggering cell apoptosis [74]. Recent data showed also that it is able to 
display the same toxicity in mouse macrophages (in press). The fact that its action is 
towards NF- B, a transcription factor with pivotal biological role in immune responses and 
involved in several disorders such as cancer and inflammatory disease [82], makes this 
toxin a potential and attractive tool for treating diseases where overexpression of NF- B is 
reported. Actually, other AB toxins, such as DT or anthrax, are successfully used in the 
targeting of distinct molecules [64, 113]. The replacement of domains, promoting specific 
targeting, allowed by distinct structure-function organization (characteristic of these toxins) 
is a concept widely exploited in therapy. In AIP56 toxin, besides the two majors domains 
that characterize this toxin (A and B domains), the existence of a putative 
region/subdomain within the C-terminal B domain that may correspond to a receptor 
binding region, raised the possibility of directing AIP56 to cells other than phagocytes by 
replacement of this putative region. For this purpose, and aiming to direct the toxin to 
specific cancer cells, it was considered the replacement of AIP56 putative receptor 
binding region by ligands whose membrane receptors are overexpressed in cancer cells. 
Membrane signing as well as membrane receptors overexpression are the hallmark of a 
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cancer cell, and are becoming increasingly important in cancer cell therapy, being 
harnessed as targets of the delivery of drugs [126]. Given this overexpression, the 
biological signal is often amplified.  
In this work, the putative receptor binding domain was successfully replaced by 
interleukin-3, whose receptor (IL-3R) is over-expressed at membrane of Acute Myeloid 
Leukemia (AML) cells [67, 127] and the toxicity induced by this chimera analyzed by 
detection of cleavage of NF- B p65 subunit, localized in the cytosol, as indicative of 
enzymatic activity and arrival of AIP56-IL3 or AIP56 domain into the cytosolic 
compartment. Moreover, it was also analyzed of its ability to trigger apoptosis in these 
cells.  
As an AB toxin, the AIP56 intoxication process is characterized by four main steps: 
binding to cell receptor, internalization, translocation and intracellular effect. The detection 
of the proteolytic activity towards p65 will indicate that, necessarily, the chimera AIP56-IL3 
successfully completed this route composed by the 4 steps above mentioned. 
In this work, it was not observed cleavage of p65 when AIP56-IL3 was incubated 
with AML cells, in none of the concentrations and time tested. Accordingly, signs of 
apoptosis were not observed in these cells. Given that in the present work it was shown 
that correct folding of the AIP56 domain was succeeded, as supported by p65 cleavage 
upon incubation of AIP56-IL3 with in vitro translated p65 and cellular p65 from AML cell 
lysates, the absence of p65 cleavage when the chimera was incubated with living cells 
could have been due to: (i) unfolding of the IL3 domain, leading to failure in the first step 
of the intoxication, i.e., binding to the cell; or (ii) failure in the translocation process. The 
correct fold of the binding domain is pivotal for recognition of its receptor which then 
allows internalization to occur. It is known that the binding of IL3 to its receptor causes 
rapid receptor-mediated endocytosis [68]. Therefore, in normal situations where unfolding 
is not a limitation, the binding and subsequently internalization of the chimera should 
occur. Despite all efforts, the verification of correct folding of IL3 domain through 
internalization assays, where detection of AIP56 inside cell is indicative that the toxin has 
entered, was unsuccessful. The low sensibility of the antibody used, the demand of this 
protocol, namely, the need to control the temperature during the experiment, the 
harshness of pronase as well as DMSF to the cells, leading to its death when it is not well 
controlled, and the intracellular detection of the protein exogenously added, requiring well 
done washes, were some of the limitations found. Alternatively, detection of 
phosphorylation in specific molecules involved in downstream pathways initiated upon IL-
3 stimulation, such as in the MAPK and phosphatidylinositol 3-kinase (PI-3K)/AKT 
pathway [128, 129], proliferation bioassay of TF-1 cells (a factor-dependent human 
erythroleukemic cell line) [130], or detection of binding by 125I-labeled IL-3, could be 
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alternatives to assess binding of IL-3 to its receptor and supportive of its correct folding. 
Perhaps relevant, is the fact that the refolding process selected in the present work, i.e. 
direct dialysis against Tris-NaCl, may have prevented proper folding of IL-3. As mentioned 
before, active chimeric proteins composed of DT fused to IL-3 have been obtained 
through refolding process [17, 97, 100, 106]. However, in this case, refolding was first 
done by dialysis against IL-3 buffer before buffer exchange to Tris-NaCl during the 
purification process. Despite the same refolding process has been also used for AIP56-
IL3 during small-scale testing, chimeric protein obtained this way remain to be tested with 
AML cells. Alternatively, the fusion of AIP56 with IL-3 may simply compromise the correct 
folding of IL-3 or the translocation process precluded, either due to incorrect folding or 
rigidity of the translocation region, or because the boundaries of the putative AIP56 
binding region, replaced in the chimera by IL-3, may have been wrongly defined and, 
consequently, some amino acid residues, important for translocation, removed. In this 
respect, it should be noted that  putative binding region has been defined based 
on limited proteolysis experiments 
structure, and, therefore, exact boundaries of the AIP56 binding/translocation regions are 
not yet established. Regarding the possible rigidity of the translocation region, this may 
arise from the fusion of the two independent molecules, AIP56 toxin and IL-3, which can 
produce a chimera with considerable structural rigidity, unable to undergo essential 
conformational changes for insertion into the membrane and, therefore, compromising the 
translocation process. Indeed, similarly to other single chain toxins, such as DT, AIP56 
needs to suffer conformational changes, triggered by acidic pH within endosomes, which 
allow its translocation into the cell cytosol by a not yet defined mechanism. In case of DT, 
a well understood single chain toxin, it is known that endosome acidification triggers a 
conformational change of the B subunit, facilitating insertion of the translocation domain 
into the membrane, which forms a cation selective pore. At low pH, the catalytic subunit 
also unfolds, becoming hydrophobic, and translocating across the formed channel to the 
cytosol [54]. Another aspect to consider is that AIP56-IL3 was produced with an additional 
N-terminal tag composed of six histidines and a TEV cleavable site that was not removed 
during the purification process. Thus, it cannot be disregarded that this tag can somehow 
prevent or obstruct insertion and translocation across the membrane. Alternatively, it may 
happen that, in contrast to other AB toxins, the full length toxin is required for the process 
to occur. Finally, it is reported that some AB toxins, such as DT and the group of binary 
toxins, such as anthrax toxin, require host cell chaperones or others cytosolic factors to 
help in both translocation and refolding of the A domain [37, 131-133]. Given that the 
molecular mechanisms and contributors for these processes are still unknown for AIP56, 
and, so far, it has been shown that AIP56 only targets neutrophils and macrophages, the 
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lack of some promoters in AML cells or the distinct endosomal membrane composition, 
may also have to be taken into account. Indeed, in the present study, no toxicity was 
observed upon incubation of AML cells with AIP56, strongly supporting the absence of a 
specific receptor for AIP56 in these cells. However, as the internalization assays did not 
work properly, it cannot be discarded that the intoxication process has failed due to 
lacking of components in AML cells other than the membrane receptor.  
Considering the above mentioned limitations, a parallel and complementary 
experiment aiming at delivering the AIP56 catalytic domain into AML cells by an 
alternative system was considered. For this purpose, the choice fell on the anthrax LF/PA 
delivery system, as it was previously successfully used for AIP56 [74]. Anthrax toxin, 
secreted by Bacillus anthracis, is composed by a B unit, called protective antigen (PA), 
which binds to anthrax toxin receptor (ATR) and is responsible for the delivery into cells of 
two alternative enzymatic A subunits: lethal factor (LF) and/or edema factor (EF). PA 
binds to ATR and upon cleavage by a furin proteases, releases a smaller fragment (PA20) 
extracellularly, while the remaining fragment (PA63) begins the assembly of the toxin 
complex by self-association, resulting in formation of a heptameric or octameric prepore 
that finally bind up to a maximum of three or four molecules of LF or EF, respectively. 
Subsequently, occurs endocytosis and trafficking of this complex to the acid endosomal 
compartment. Low pH triggers a conformational change in PA, leading to formation of 
pores by its insertion into the endosome membrane. This way, the translocation of LP or 
EF to cytosol is promoted [134]. PA is a central component of this system because it 
mediates the entry of LF or EF into cells but it can also translocate chimeric proteins 
containing PA-
cell types [134-136] , allowing the wide use of this system as vehicle to delivery proteins 
into the cell cytosol. It has been demonstrated that the first 263 amino acids of LF, 
corresponding to the N-terminal, are the minimal region required to allow recognition and 
binding to PA and subsequently uptake into cell of fused polypeptides [111]. Promising 
results were obtained when the anthrax LF/PA delivery system was used to deliver the 
AIP56 catalytic domain into AML cells because cleavage of p65 was observed, showing 
that, when inside these cells, AIP56 is able to perform its enzymatic activity. However, 
apoptosis could not be observed in the conditions tested. Three main reasons may 
account to this circumstance: (i) low expression level of the ATR in AML cells, resulting in 
insufficient amounts of internalized toxin for causing p65 depletion; indeed, although 
anthrax toxin is able to enter almost any cell type, its major target are professional 
phagocytes [134-136]; (ii) need for longer incubation periods; and/or (iii) need of pro-
apoptotic co-stimulatory stimuli. 
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In this work, studies on AIP56 toxin were mainly focused on directing it to cells other than 
macrophages through protein ligands that promote specific targeting. Its ability to induce 
toxicity in specific cells was evaluated.  
The replacement of the putative receptor binding domain by interleukin-3 was 
performed, yielding AIP56-IL3 chimeric protein. NF- B p65 cleavage and its ability to 
induce cell death were assessed in AML cells. Cleavage of p65 by this chimera was not 
observed in AML cells. Given the limitations found during the course of the project it 
remains to be elucidated whether the absence of p65 cleavage in living cells resulted from 
incorrect folding of the AIP56-IL3 chimera. Taking into account the success of the chimera 
DT-IL3, obtained by refolding trough a two-step dialysis protocol, it should be considered 
carrying out experiments on AML cells with AIP56-IL3 chimera obtained according to the 
procedure used for the refolding of DT-IL3. Alternatively, other receptor binding moieties 
may be considered for replacing the AIP56 binding region, e.g., single chain antibodies 
towards IL-3 receptor [137] ceptor 
binding region would be greatly helpful. 
Finally, using the anthrax LF/PA delivering system for delivering AIP56 into AML 
cells, allow exploring the effect of targeting p65 into these cells under different 
circumstances and conclude about the feasibility of using AIP56 catalytic domain as 
biomedical tool. 
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          His-Tag  pET28a           NdeI    TEV cleavage 
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatatggagaatctttattttcagagcaac 
 M  G  S  S  H  H  H  H  H  H  S  S  G  L  V  P  R  G  S  H  M  E  N  L  Y  F  Q  S  N          
aacgataaaccagatgcaagcgatgacaagtacgcagactacgtggtacgtctaggttcggaacatccactaaaccatactcagatc  
 N  D  K  P  D  A  S  D  D  K  Y  A  D  Y  V  V  R  L  G  S  E  H  P  L  N  H  T  Q  I 
Attgaactttcctctgcagtatcgagggctgtccttcttagttacccaaatataatagaccgatacaccgctgcagcaactgaatat 
 I  E  L  S  S  A  V  S  S  A  V  L  L  S  Y  P  N  I  I  D  R  Y  T  A  A  A  T  E  Y 
acggtgatcgatgctttatttcattcgcctacctttcgacatatcgtttcttttggtcttcataatcagcaagagaaccttggtcat 
 T  V  I  D  A  L  F  H  S  P  T  F  R  H  I  V  S  F  G  L  H  N  Q  Q  E  N  L  G  H   
Attcgatatactaatgaatatgaaattaacaataatcgcgaagatgagttctccttagtgagcgaggtaagctacgacgatataaaa 
 I  R  Y  T  N  E  Y  E  I  N  N  N  R  E  D  E  F  S  L  V  S  E  V  S  Y  D  D  I  K   
Agctctaatgctcagcaagttcccctagttgcattttatgaagcgcgagaggaccgcgcgacgggcacgcctatcgtaaatatgggt 
 S  S  N  A  Q  Q  V  P  L  V  A  F  Y  E  A  R  E  D  R  A  T  G  T  P  I  V  N  M  G 
gtagctCctagtcttttttctggcagatatagttggtggcaagaagcattaatccatgaaattgttcatcacgttacaggctctagt 
 V  A  P  S  L  F  S  G  R  Y  S  W  W  Q  E  A  L  I  H  E  I  V  H  H  V  T  G  S  S   
Gatactcatgaagaaaataagcaagggcctactgaaattttagctcaaatggtcgcggcggaacttcattgggcgataccaaccttt 
 D  T  H  E  E  N  K  Q  G  P  T  E  I  L  A  Q  M  V  A  A  E  L  H  W  A  I  P  T  F   
aaaggataTtcagatcctgcgagggtcgaagcgatacaagagcgcgatttccactccttgttgaatatgttccagagacacggcagt 
 K  G  Y  S  D  P  A  R  V  E  A  I  Q  E  R  D  F  H  S  L  L  N  M  F  Q  R  H  G  S   
gaattaggctttctgttcaccagattagctacgattgccaaaggtaagaaagcttcgcctgacttcggcaccctgacctctttttgc 
 E  L  G  F  L  F  T  R  L  A  T  I  A  K  G  K  K  A  S  P  D  F  G  T  L  T  S  F  C  
tcggaaggtattagcagttttcctaaatatcccgatcacgatgatgatttcaacgggggcggcgccttttttctccctagcgctagc 
 S  E  G  I  S  S  F  P  K  Y  P  D  H  D  D  D  F  N  G  G  G  A  F  F  L  P  S  A  S   
Gccgacagttcagttgaatgcacttttgatgtactaaatcgaatcgagcctgttgatgactcaattaaatttgaaggggggaatttg 
 A  D  S  S  V  E  C  T  F  D  V  L  N  R  I  E  P  V  D  D  S  I  K  F  E  G  G  N  L   
ctaattaaaaatgacttcaaaaacctaaatttacgtgttgcacagcttagctttttgaacgcaaaaaaaggtagcggattttacaga 
 L  I  K  N  D  F  K  N  L  N  L  R  V  A  Q  L  S  F  L  N  A  K  K  G  S  G  F  Y  R  
aaaaattgggattcttggaaatcctggtatcaagcttcttcatggaagaatgggctcaattccggtctatatgagctcgctcccatg 
 K  N  W  D  S  W  K  S  W  Y  Q  A  S  S  W  K  N  G  L  N  S  G  L  Y  E  L  A  P  M  
Acccagacaacgcccttgaagacaagctgggttaactgctctaacatgatcgatgaaattataacacacttaaagcagccacctttg 
 T  Q  T  T  P  L  K  T  S  W  V  N  C  S  N  M  I  D  E  I  I  T  H  L  K  Q  P  P  L   
Cctttgctggacttcaacaacctcaatggggaagaccaagacattctgatggaaaataaccttcgaaggccaaacctggaggcattc 
 P  L  L  D  F  N  N  L  N  G  E  D  Q  D  I  L  M  E  N  N  L  R  R  P  N  L  E  A  F  
Aacagggctgtcaagagtttacagaacgcatcagcaattgagagcattcttaaaaatctcctgccatgtctgcccctggccacggcc 
 N  R  A  V  K  S  L  Q  N  A  S  A  I  E  S  I  L  K  N  L  L  P  C  L  P  L  A  T  A   
Gcacccacgcgacatccaatccatatcaaggacggtgactggaatgaattccggaggaaactgacgttctatctgaaaacccttgag 
 A  P  T  R  H  P  I  H  I  K  D  G  D  W  N  E  F  R  R  K  L  T  F  Y  L  K  T  L  E   
aatgcgcggctcaacagacgactttgagcctcgcgatcttttagctcgag 
 N  A  Q  A  Q  Q  T  T  L  S  L  A  I  F  END L  E 
               XhoI 
Figure 1S. Nucleotide and amino acid sequences of AIP56-IL3 construct. AIP56 sequence is indicated in black, IL3  in 
purple, pET28a+ and histidines tag in red, TEV cleavage site in green,  NdeI restriction site in blue and Sac I restriction site 
in orange. 
 
 
 
 
Figure 2S. Soluble refolded AIP56-IL3. Culture of the E. coli BL21 (DE3) 
competent cells transformed with plasmid pETAIP56-IL3 were grown at 30ºC, 
with shaking (150 rpm). When the culture reached an OD of 0.6 at 600 nm, 
recombinant protein expression was induced with 0.5 mM IPTG and incubated 
for 2h. AIP56-IL3 were isolated from E. coli cell pellets, solubilized, dialysed 
against Tris-NaCl and analyzed by Coomassie Blue stained 12% acrylamide 
SDS-PAGE. The overexpressed protein band at ~60.4 kDa is the protein of 
interest. 
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Figure 3S. Analysis of the refolding process. A) Denatured AIP56-IL3 was refolded by dialysis or dilution and dialysis 
against PBS with 10 % glycerol, Tris-NaCl, Tris-NaCl with 10 % glycerol or IL-3 Buffer (indicated on top of the gel). The 
insoluble and soluble fraction of refolded AIP56-IL3 was analyzed by Coomassie-blue stained 12% acrylamide SDS-PAGE. 
Molecular weight of expressed protein is ~60.4 kDa. It was also assessed whether the addition of glycerol to Tris-NaCl 
refolding buffer improved the refolding process [138]. However, the results showed that its effect does not significantly 
improve the refolding process, namely the amount of soluble protein produced as well as p65 cleavage efficiency. 
Therefore, its addition was discarded. B) Catalytic activity of AIP56-IL3. Incubation of in vitro translated 35S-labeled 
sbp65Rel, in presence of the IL-3 buffer (IL-3 buf.), with AIP56 in Tris-NaCl and AIP56-IL3 in Tris-NaCl, refolded in 
conditions indicated as 1, 2 or 3 (see below) resulted in p65 cleavage. When AIP56-IL3 was dialyzed against IL-3 Buffer 
A 
B 
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(indicated as 4 in the blot at right) no cleavage was observed. The mix was incubated for 2 hours at 22°C with 20 nM of the 
indicated protein and the p65 cleavage assessed by autoradiography. The position of full length (p65) and cleaved (cl-p65) 
p65 are indicated. 
1. Dialysis against Tris-NaCl with 10 % glycerol 
2. Dilution against IL-3 buffer (IL-3 Buf.) and dialysis against Tris/NaCl 
3. Dilution against IL-3 buffer and dialysis against IL-3 buffer and dialysis against Tris-NaCl 
4. Dilution and dialysis against IL-3 buffer 
 
 
 
Figure 4S. Internalization assays of AIP56-IL3. AML cells were incubated with 200 nM AIP56 (11.2 µg/mL) or AIP56-IL3 
(12 µg/mL) for 30 min on ice, transferred to 37ºC for 10 min and transferred again to ice for 5 min. Cells were washed twice 
with ice-cold PBS and incubated, when indicated, for 10 min on ice with Pronase E. Pronase E was inactivated with PMSF 
and the cells were washed twice with ice cold PBS. Cells untreated, treated with pronase E or treated with protein but 
without incubation with pronase E were used as controls. Internalized AIP56 was detected by Western blotting. In order to 
check the efficiency of Pronase E, a similar protocol was applied to cells where the 10 min internalization step at 37ºC has 
been replaced by 10 min incubation on ice to prevent internalization. 
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